Tunable applicator and methods for making and using same
The applicator system with force-triggered mechanical transitions addresses the inconsistency in microneedle array insertion by ensuring controlled and repeatable insertion into biological tissue, enhancing delivery and sampling reliability.
Patent Information
- Application Number
- PCT/US2026/027674
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-11
- Publication Date
- 2026-11-12
AI Technical Summary
Existing microneedle arrays face challenges in reliable and reproducible insertion into biological tissue due to user-dependent force application, leading to inconsistent delivery or sampling performance.
An applicator system with structural elements that undergo a mechanical transition at a predetermined force threshold, facilitating controlled and repeatable insertion of microneedle arrays into biological tissue.
The applicator system ensures consistent and reliable insertion of microneedle arrays by providing a user-perceptible indication and regulating insertion depth, independent of user variability.
Smart Images

Figure US2026027674_12112026_PF_FP_ABST
Abstract
Description
ATTORNEY DOCKET NO. STFD-037-PCT PATENTTUNABLE APPLICATOR AND METHODS FOR MAKING AND USING SAMECROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. provisional application No. 63 / 803,294, which was filed May 9, 2025, entitled “MICRONEEDLE ARRAY PATCHES HAVING A TUNABLE APPLICATOR COMPONENT AND METHODS FOR MAKING AND USING SAME,” and is incorporated by reference in its entirety.FIELD OF INVENTION
[0002] The present disclosure relates to microneedle-based devices and methods, and more particularly to applicators configured to insert microneedle arrays into biological tissue with a controlled, force-triggered mechanical response.BACKGROUND
[0003] Biological tissues have been actively explored as targets for minimally invasive drug delivery, diagnostic sampling, and fluid exchange. Delivery or sampling through biological tissue may involve penetrating one or more barrier layers or tissue surfaces, such as epithelial, mucosal, dermal, organ, or other tissue structures that provide mechanical resistance to access. Accessing underlying tissue regions can offer advantages over conventional intravenous (IV) administration, including reduced pain, localized delivery, avoidance of first-pass metabolism, reduced systemic exposure, and the potential for self-administration or minimally invasive clinical procedures.
[0004] Microneedle arrays, also referred to as micro-array patches (MAPs), have been developed to facilitate intradermal access. These devices include arrays of micrometer-scale projections capable of penetrating the skin to deliver therapeutic agents or to extract biological fluids such as interstitial fluid. Microneedle-based systems have been applied in a range of contexts, including drug delivery, diagnostics, and cosmetic treatments. Conventional microneedles are typically fabricated using molding-based techniques and may be solid or hollow structures with fixed geometries.
[0005] Despite these advances, reliable and reproducible insertion of microneedle arrays into tissue remains a challenge. Existing applicators and insertion mechanisms often rely on springbased, latch-based, or velocity-driven systems, or on manual application of force by a user. As aATTORNEY DOCKET NO. STFD-037-PCT PATENTresult, insertion depth and efficacy can vary depending on user technique, applied force, and device configuration. This variability can lead to inconsistent delivery or sampling performance and may limit the effectiveness of microneedle-based systems in practical applications.SUMMARY OF THE INVENTION
[0006] Aspects of the present disclosure are directed to applicators for inserting microneedle arrays into biological tissue. In certain embodiments, an applicator includes one or more structural elements configured to transmit an applied force to a microneedle array, where the structural elements are further configured to undergo a mechanical transition when the applied force reaches a predetermined force threshold. The mechanical transition facilitates insertion of the microneedle array into the tissue in a controlled and repeatable manner.
[0007] In some embodiments, the mechanical transition comprises fracture, deformation, or other structural change of one or more portions of the applicator. The structural elements may include one or more frangible or compliant members, such as struts or related structures, configured to define the predetermined force threshold. In certain implementations, the mechanical transition provides a user-perceptible indication of actuation and may occur only once during use.
[0008] In some embodiments, the applicator is configured as a standalone device or is configured to be coupled to a microneedle array, such as via a reversible or irreversible coupling interface. The applicator may be configured to position the microneedle array relative to a tissue surface prior to insertion and to deliver force along a defined load path to facilitate controlled insertion.
[0009] Further aspects include kits comprising a microneedle array and the applicator, as well as methods of inserting a microneedle array into a subject by applying force to the applicator until the predetermined force threshold is reached, thereby causing the mechanical transition and insertion of the microneedle array.
[0010] In some embodiments, the microneedle array is configured for delivery of a substance to the subject or extraction of a biological fluid from the subject. The microneedles may include structural features such as lattice microstructures configured to facilitate fluid transport, storage, or delivery.BRIEF DESCRIPTION OF THE DRAWINGSATTORNEY DOCKET NO. STFD-037-PCT PATENT
[0011] The present disclosure will become more fully understood from the detailed description and the accompanying drawings, wherein:
[0012] FIG. 1 is a perspective view of an applicator system in accordance with an embodiment of the present disclosure;
[0013] FIG. 2A is a top view of the applicator system shown in FIG. 1 having 3 structural elements;
[0014] FIG. 2B is a top view of the applicator system shown in FIG. 1 having 8 structural elements;
[0015] FIG. 2C is a top view of the applicator system shown in FIG. 1 having 16 structural elements;
[0016] FIG. 3 is a bottom perspective view of the applicator system shown in FIG. 1;
[0017] FIG. 4 is a cross sectional view taken along line I-I of FIG. 1;
[0018] FIG. 5 is a perspective bottom view of an applicator system in accordance with an embodiment of the present disclosure;
[0019] FIG. 6 is a perspective bottom view of an applicator system in accordance with an embodiment of the present disclosure;
[0020] FIG. 7 is a cross sectional view taken along line II-II of FIG. 6;
[0021] FIG. 8A is a perspective bottom view of an applicator system in accordance with an embodiment of the present disclosure;
[0022] FIG. 8B is a side cross-sectional view of the applicator system shown in FIG. 8A;
[0023] FIG. 9A is a diagram of the applicator system shown in FIGS 8A-8B with a biological active contained in a reservoir;
[0024] FIG. 9B is a diagram of the applicator system shown in FIG. 9A with the biological active released from the reservoir;
[0025] FIG. 10A is a perspective view of an applicator system in accordance with an embodiment of the present disclosure;
[0026] FIG. 10B is a perspective view of the applicator system shown in FIG. 10A penetrated into skin;
[0027] FIG. 10C is a perspective view of the applicator system shown in FIGS. 10A-10B with a biological active being released into skin;
[0028] FIG. 11 is a perspective view of an applicator system in accordance with an embodiment of the present disclosure;ATTORNEY DOCKET NO. STFD-037-PCT PATENT
[0029] FIG. 12A is a perspective view of the applicator system shown in FIG. 11 having varied geometry;
[0030] FIG. 12B is a cross sectional side view of the applicator system shown in FIG. 12A;
[0031] FIG. 13 is a perspective view of the applicator system shown in FIG. 11 having varied geometry;
[0032] FIG. 14 is a perspective view of the applicator system shown in FIG. 11 having varied geometry;
[0033] FIG. 15A is a schematic view of an applicator system in accordance with an embodiment of the present disclosure;
[0034] FIG. 15B is a schematic view of an applicator system in accordance with an embodiment of the present disclosure;
[0035] FIG. 15C is a schematic view of an applicator system in accordance with an embodiment of the present disclosure.
[0036] FIG. 16 is a graphical representation of force as a function of the number of structural elements;
[0037] FIG. 17 is a graphical representation of force as a function of structural element thickness;
[0038] FIG. 18A is a graphical representation of force as a function of the number of structural elements;
[0039] FIG. 18B is a graphical representation of force as a function of structural element cross-sectional area;
[0040] FIG. 18C is a set of force-displacement curves for applicator systems formed from different polymeric materials;
[0041] FIG. 18D is a graphical representation of activation force measurements for applicator systems formed from different polymeric materials;
[0042] FIG. 19A is a graphical representation of penetration depth measurements for microneedle array patches applied using different application methods;
[0043] FIG. 19B is a set of optical coherence tomography images showing penetration profdes of microneedles inserted into tissue using different application methods; and
[0044] FIG. 20A is a top perspective view of an applicator system in accordance with an embodiment of the present disclosure; andATTORNEY DOCKET NO. STFD-037-PCT PATENT
[0045] FIG. 20B is a top perspective view of the applicator system shown in FIG. 20A with the with a distal portion separated from a proximal portion.DETAILED DESCRIPTION
[0046] The following description of the embodiment s) is merely exemplary in nature and is in no way intended to limit the invention, its application, or uses.
[0047] The description of illustrative embodiments according to principles of the present disclosure is intended to be read in connection with the accompanying drawings, which are to be considered part of the entire written description. In the description of embodiments of the invention disclosed herein, any reference to direction or orientation is merely intended for convenience of description and is not intended in any way to limit the scope of the present disclosure. Relative terms such as “lower,” “upper,” “horizontal,” “vertical,” “above,” “below,” “up,” “down,” “top” and “bottom” as well as derivatives thereof (e.g., “horizontally,” “downwardly,” “upwardly,” etc.) should be construed to refer to the orientation as then described or as shown in the drawing under discussion. These relative terms are for convenience of description only and do not require that the apparatus be constructed or operated in a particular orientation unless explicitly indicated as such. Terms such as “attached,” “affixed,” “connected,” “coupled,” “interconnected,” and similar refer to a relationship wherein structures are secured or attached to one another either directly or indirectly through intervening structures, as well as both movable or rigid attachments or relationships, unless expressly described otherwise. Moreover, the features and benefits of the disclosure are illustrated by reference to the exemplified embodiments. Accordingly, the invention expressly should not be limited to such exemplary embodiments illustrating some possible non-limiting combination of features that may exist alone or in other combinations of features; the scope of the invention being defined by the claims appended hereto.
[0048] Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. For example, Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley & Sons (New York, NY 1994), provide one skilled in the art with a general guide to many of the terms used in the present application. Additionally, the practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (includingATTORNEY DOCKET NO. STFD-037-PCT PATENTrecombinant techniques), microbiology, cell biology, and biochemistry, which are within the skill of the art. Such techniques are explained fully in the literature, such as, "Molecular Cloning: A Laboratory Manual", 2nd edition (Sambrook et al., 1989); "Oligonucleotide Synthesis" (M.J. Gait, ed., 1984); "Animal Cell Culture" (R.I. Freshney, ed., 1987); "Methods in Enzymology" (Academic Press, Inc.); "Handbook of Experimental Immunology", 4th edition (D.M. Weir & C.C. Blackwell, eds., Blackwell Science Inc., 1987); "Gene Transfer Vectors for Mammalian Cells" (J.M. Miller & M.P. Calos, eds., 1987); "Current Protocols in Molecular Biology" (F.M. Ausubel et al., eds., 1987).
[0049] As used in the present disclosure and claims, the singular forms “a”, “an” and “the” include plural forms unless the context clearly dictates otherwise.
[0050] It is understood that wherever embodiments are described herein with the language “comprising” otherwise analogous embodiments described in terms of “consisting of’ and / or “consisting essentially of’ are also provided. It is also understood that wherever embodiments are described herein with the language “consisting essentially of’ otherwise analogous embodiments described in terms of “consisting of’ are also provided.
[0051] The term "about" as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ±20%, ±10%, ±5%„ ±1%, or ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods. For recitation of numeric ranges herein, each intervening number therebetween with the same degree of precision is explicitly contemplated. For example, for the range of 6-9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the numbers 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6,9, and 7.0 are explicitly contemplated.
[0052] The term “and / or” as used in a phrase such as “A and / or B” herein is intended to include both A and B; A or B; A (alone); and B (alone). Likewise, the term “and / or” as used in a phrase such as “A, B, and / or C” is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0053] As used herein in the specification and in the claims, “or” should be understood to have the same meaning as “and / or” as defined above. For example, when separating items in a list, “or” or “and / or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items.ATTORNEY DOCKET NO. STFD-037-PCT PATENTOnly terms clearly indicated to the contrary, such as “only one of or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e. “one or the other but not both”) when preceded by terms of exclusivity, “either,” “one of,” “only one of,” or “exactly one of.” “Consisting essentially of,” when used in the claims, shall have its ordinary meaning as used in the field of patent law.
[0054] The term “at least” prior to a number or series of numbers (e.g., “at least two”) is understood to include the number adjacent to the term “at least,” and all subsequent numbers or integers that could logically be included, as clear from context. When “at least” is present before a series of numbers or a range, it is understood that “at least” can modify each of the numbers in the series or range. Ranges provided herein are understood to include all individual integer values and all subranges within the ranges.
[0055] As used herein, the term “animal” includes, but is not limited to, humans and non-human vertebrates such as wild animals, rodents, such as rats, ferrets, and domesticated animals, and farm animals, such as dogs, cats, horses, pigs, cows, sheep, and goats. In some embodiments, the animal is a mammal. In some embodiments, the animal is a human. In some embodiments, the animal is a non-human mammal.
[0056] As used herein, the terms “comprising” (and any form of comprising, such as “comprise,” “comprises,” and “comprised”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”), or “containing” (and any form of containing, such as “contains” and “contain”), are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
[0057] “Optional” or “optionally” means that the subsequently described event, circumstance, or material may or may not occur or be present, and that the description includes instances where the event, circumstance, or material occurs or is present and instances where it does not occur or is not present.
[0058] The term “diagnosis” or “prognosis” as used herein refers to the use of information (e.g., genetic information or data from other molecular tests on biological samples, signs and symptoms, physical exam findings, cognitive performance results, etc.) to anticipate the most likely outcomes, timeframes, and / or response to a particular treatment for a given disease, disorder, or condition, based on comparisons with a plurality of individuals sharing common nucleotide sequences,ATTORNEY DOCKET NO. STFD-037-PCT PATENTsymptoms, signs, family histories, or other data relevant to consideration of a patient’s health status.
[0059] As used herein, the phrase “in need thereof’ means that the animal or mammal has been identified or suspected as having a need for the particular method or treatment. In some embodiments, the identification can be by any means of diagnosis or observation. In any of the methods and treatments described herein, the animal or mammal can be in need thereof. In some embodiments, the subject in need thereof is a human seeking prevention of a disease or disorder (e g., a bone disorder).
[0060] The terms “subject,” “individual,” and “patient” are used interchangeably herein to refer to a vertebrate, a mammal in some embodiments, a human in some embodiments. Mammals include, but are not limited to, murine, simians, humans, farm animals, cows, pigs, goats, sheep, horses, dogs, sport animals, and pets. Tissues, cells and their progeny obtained in vivo or cultured in vitro are also encompassed by the definition of the term “subject.” The term “subject” is also used throughout the specification in some embodiments to describe an animal from which a cell sample is taken or an animal to which a disclosed cell or nucleic acid sequences have been administered. In some embodiments, the subject is a human. For treatment of those conditions which are specific for a specific subject, such as a human being, the term “patient” may be interchangeably used. In some embodiments, in the description of the present disclosure, the term “patient” will refer to human patients suffering from a particular disease or disorder. In some embodiments, the subject may be a non-human animal. The term “mammal” encompasses both humans and non-humans and includes but is not limited to humans, non-human primates, canines, felines, murine, bovines, equines, caprine, and porcines. In some embodiments, the mammal is a donkey, camel, rabbit, guinea pig, horse, pig, cow, cat, dog, rat, mouse, monkey, non-human primate, ape, or human. In some embodiments, the term “subject” is a human diagnosed with or suspected of having a bone disorder, such as osteonecrosis.
[0061] Aspects of the present disclosure are directed to applicator systems configured to facilitate insertion of microneedle arrays into biological tissue in a controlled and repeatable manner. As used herein, biological tissue may include skin, mucosal tissue, organ tissue, tumor tissue, ocular tissue, vascular tissue, or other biologic tissues suitable for delivery, sampling, sensing, or fluid exchange applications. In particular embodiments, the applicator systems include one or moreATTORNEY DOCKET NO. STFD-037-PCT PATENTstructural elements configured to undergo a mechanical transition in response to an applied force, thereby regulating insertion of a microneedle array.
[0062] Referring to FIGS. 1-4, an applicator system 100 according to an embodiment of the present disclosure is disclosed. The applicator system 100 includes a body 104 and one or more structural elements 108 operably coupled to the body 104. The structural elements 108 are configured to transmit an applied force from the body 104 to a microneedle array 112. The microneedle array 112 may be supported on or coupled to a substrate 116, such that the applied force is delivered along a defined load path from the body 104, through the structural elements 108, and to the substrate 116 and microneedle array 112.
[0063] In the illustrated embodiment, the structural elements 108 comprise one or more breakable or compliant connections configured to undergo a mechanical transition when the applied force reaches a predetermined force threshold. The mechanical transition may include, for example, fracture, elastic deformation, buckling, or other structural reconfiguration of at least a portion of the structural elements 108. The occurrence of the mechanical transition may result in a change in stiffness, resistance, or load transfer characteristics of the applicator system 100, thereby facilitating insertion of the microneedle array 112 into the tissue.
[0064] In some embodiments, the applicator system 100 is configured such that the mechanical transition occurs at a predetermined force threshold that is defined by one or more properties of the structural elements 108, including geometry, material composition, and / or dimensional characteristics. By configuring the structural elements 108 to transition at the predetermined force threshold, the applicator system 100 can provide controlled and repeatable insertion of the microneedle array 112 independent of user variability.
[0065] In certain implementations, the mechanical transition of the structural elements 108 is irreversible, such that once the predetermined force threshold is reached and the transition occurs, the applicator system 100 is configured for single-use operation. In other implementations, the mechanical transition may be partially or fully reversible, depending on the configuration of the structural elements 108.
[0066] In some embodiments, the applicator system 100 may be configured to provide a user-perceptible indication when the mechanical transition occurs. For example, the transition may generate an audible, tactile, or visual indication associated with a change in structural state of theATTORNEY DOCKET NO. STFD-037-PCT PATENTstructural elements 108, thereby signaling that sufficient force has been applied for insertion of the microneedle array 112.
[0067] The applicator system 100 may be configured as a standalone device or may be configured to be coupled to the microneedle array 112 and substrate 116 to form an integrated assembly. In some embodiments, the applicator system 100 includes a coupling interface 120 configured to engage the substrate 116. The coupling interface 120 may be configured for reversible or irreversible coupling and may include one or more alignment features configured to position the microneedle array 112 relative to a tissue surface prior to insertion.
[0068] In operation, a user may apply a force to the body 104 of the applicator system 100, causing the force to be transmitted through the structural elements 108 toward the microneedle array 112. As the applied force increases and reaches the predetermined force threshold, the structural elements 108 undergo the mechanical transition, resulting in insertion of the microneedle array 112 into the tissue to a controlled depth.
[0069] The applicator systems described herein may be used in conjunction with microneedle arrays configured for delivery of a substance to a subject or extraction of a biological fluid from a subject. In this manner, the applicator system 100 provides a controlled mechanical interface for access to biological tissue, improving consistency and reliability relative to conventional insertion approaches that rely on user-applied force without a defined actuation threshold.
[0070] Continuing with FIGS. 1-4, the applicator system 100 is configured to facilitate controlled insertion of the microneedle array 112 into biological tissue through a force-regulated mechanical response. The applicator system 100 includes the body 104 and one or more structural elements 108 operably coupled to the body 104, where the structural elements 108 are configured to transmit an applied force from the body 104 to the microneedle array 112 supported on the substrate 116.
[0071] The body 104 comprises a support structure configured to be engaged by a user to apply a force to the applicator system 100. In some embodiments, the body 104 includes a proximal portion 124 configured for user contact and a distal portion 128 configured to interface with the structural elements 108. The proximal portion 124 is coupled to the distal portion 128 via the one or more structural elements 108. In some embodiments, a bottom portion of the proximal portion 124 may be coupled to a top portion of the distal portion 128 via the structural elements 108. The body 104 may define one or more internal features, including cavities, guide surfaces, or support structures, configured to direct and distribute the applied force to the structural elements 108. In certainATTORNEY DOCKET NO. STFD-037-PCT PATENTembodiments, the body 104 is substantially rigid to ensure that deformation of the applicator system 100 occurs primarily within the structural elements 108 rather than the body 104.
[0072] The structural elements 108 are configured to transmit force from the body 104 to the substrate 116 and microneedle array 112 and to undergo a mechanical transition at a predetermined force threshold. In some embodiments, the structural elements 108 comprise a plurality of members 132 extending between the body 104 and the substrate 116. As previously described, the members 132 may comprise one or more of a strut, beam, membrane, bar, truss, or combination thereof. In certain embodiments, the structural elements 108 include a plurality of members 132 configured as struts. The number of members 132 may be selected to achieve a desired force response. In some instances, the structural elements 108 include 3 or more members, such as 4 or more, such as 5 or more, such as 6 or more, such as 7 or more, such as 8 or more, such as 9 or more, such as 10 or more, such as 12 or more, such as 14 or more, such as 16 or more, such as 18 or more, such as 20 or more, such as 25 or more, and including 30 or more members. In some embodiments, the structural elements 108 include from 3 to 20 members, such as from 4 to 19 members, such as from 5 to 18 members, such as from 6 to 17 members, such as from 7 to 16 members, such as from 8 to 15 members, such as from 9 to 15 members, and including from 10 to 15 members.
[0073] Each member 132 may define a cross-sectional geometry selected to achieve a desired mechanical response. In some embodiments, the members 132 have a cross-sectional area of from 0.1 mm2to 1 mm2, such as from 0.15 mm2to 0.95 mm2, such as from 0.20 mm2to 0.90 mm2, such as from 0.25 mm2to 0.85 mm2, such as from 0.30 mm2to 0.80 mm2, such as from 0.35 mm2to 0.75 mm2, and including from 0.40 mm2to 0.70 mm2. In some instances, the cross-sectional area is from 0.12 mm2to 0.56 mm2. In some embodiments, one or more members 132 include preweakened regions configured to localize stress and initiate a mechanical transition. The preweakened regions may include reduced cross-sectional regions, notches, perforations, or other stress concentrators. The number, arrangement, and geometry of the members 132 may be selected collectively to define a desired force-displacement response of the applicator system 100.
[0074] In some embodiments, the applicator system 100 comprises a rigid component and a compliant component, wherein the rigid component maintains structural integrity and the compliant component includes the structural elements 108 configured to undergo the mechanical transition.ATTORNEY DOCKET NO. STFD-037-PCT PATENT
[0075] The structural elements 108 are configured to undergo a mechanical transition in response to an applied force. As used herein, a “mechanical transition” refers to a change in the structural configuration of one or more members 132 that alters the mechanical behavior of the applicator system 100. In some embodiments, the mechanical transition comprises fracture of at least a portion of one or more members 132. In some embodiments, the mechanical transition comprises complete fracture or breakage of the one or more members 132 from the body 104 such that the proximal portion 124 and the distal portion 128 are completely separated from each other. In other embodiments, the mechanical transition comprises elastic deformation, plastic deformation, buckling, compression, expansion, or combinations thereof. The mechanical transition may result in a change in resistance to further displacement of the body 104. For example, the applicator system 100 may exhibit a first resistance to displacement prior to the transition and a reduced resistance after the transition, thereby facilitating insertion of the microneedle array 112.
[0076] In some embodiments, the mechanical transition is irreversible, such that the members 132 do not return to their original configuration after the transition. In other embodiments, the transition may be partially or fully reversible. In certain embodiments, the mechanical transition results in displacement of one or more portions of the applicator system 100 in one or more directions, including along an X-axis, Y-axis, Z-axis, or combinations thereof. The displacement may correspond to a magnitude of 0.001 mm or more, such as 0.005 mm or more, such as 0.01 mm or more, such as 0.05 mm or more, such as 0.1 mm or more, such as 0.5 mm or more, such as 1 mm or more, such as 2 mm or more, such as 3 mm or more, such as 4 mm or more, such as 5 mm or more, such as 10 mm or more, such as 15 mm or more, such as 20 mm or more, and including 50 mm or more.
[0077] The structural elements 108 are configured such that the mechanical transition occurs when the applied force reaches a predetermined force threshold. In some embodiments, the members 132 are configured to break under an applied force of from about 5 N to about 250 N, such as from about 10 N to about 245 N, such as from 15 N to about 240 N, such as from about 20 N to about 235 N, such as from about 25 N to about 230 N, such as from about 30 N to about 225 N, such as from about 35 N to about 220 N, such as from about 40 N to about 215 N, such as from about 45 N to about 210 N, such as from about 50 N to about 200 N, such as from about 75 N to about 175 N, such as from about 100 N to about 150 N, and including from about 10 N to about 170 N.ATTORNEY DOCKET NO. STFD-037-PCT PATENT
[0078] In some embodiments, the predetermined force threshold is defined by one or more of a geometry of the members 132, a material composition of the members 132, and a dimensional characteristic of the members 132. The predetermined force threshold may be selected to correspond to a force sufficient to insert the microneedle array 112 into tissue to a desired depth, thereby reducing variability in insertion performance across users.
[0079] The structural elements 108 define a load path extending from the body 104 to the substrate 116 and microneedle array 112. The load path may be configured to transmit force along a substantially axial direction relative to the microneedle array 112. In some embodiments, the members 132 distribute the applied force across the substrate 116. In other embodiments, the load path may be configured to concentrate force in selected regions. Following the mechanical transition, the load path may change such that the force is transmitted more directly from the body 104 to the substrate 116.
[0080] In use, a user applies a mechanical force to the proximal portion 124 of the body 104. The applied force is transmitted through the structural elements 108 toward the microneedle array 112. As the applied force reaches the predetermined force threshold, the structural elements 108 undergo the mechanical transition, resulting in insertion of the microneedle array 112 into tissue. In some embodiments, the mechanical transition produces a user-perceptible indication, including an audible, tactile, or visual signal. The applicator system 100 may be configured such that the mechanical transition occurs only once during use. Following the mechanical transition, continued application of force may result in further displacement of the body 104 with reduced resistance, corresponding to advancement of the microneedle array 112 into the tissue.
[0081] Continuing with FIGS. 3-4 the applicator system 100 is coupled to the microneedle array 112 and substrate 116 to form an integrated assembly. In certain embodiments, the applicator system 100 includes the coupling interface 120 configured to mechanically engage the substrate 116 and position the microneedle array 112 relative to a tissue surface prior to insertion. The coupling interface 120 may comprise one or more mechanical engagement features configured to couple the applicator system 100 to the substrate 116. In some embodiments, the coupling interface 120 is configured for reversible coupling, such that the substrate 116 may be attached to and detached from the applicator system 100. In other embodiments, the coupling interface 120 is configured for irreversible coupling, such that the substrate 116 is permanently secured to the applicator system 100 after assembly. In certain embodiments, the coupling interface 120ATTORNEY DOCKET NO. STFD-037-PCT PATENTcomprises a snap-fit mechanism in which one or more features of the substrate 116 engage corresponding features of the applicator system 100. In other embodiments, the coupling interface 120 comprises an adhesive interface configured to bond the substrate 116 to the applicator system 100. In further embodiments, the coupling interface 120 may include one or more magnetic elements configured to facilitate coupling between the applicator system 100 and the substrate 116.
[0082] In some embodiments, the applicator system 100 and / or the substrate 116 includes one or more alignment features configured to position the microneedle array 112 relative to the applicator system 100. The alignment features may comprise one or more of a notch, a groove, a hole, a protrusion, a polygonal-shaped protrusion, a cantilever hook, or combinations thereof. In certain embodiments, the alignment features on the substrate 116 are configured to engage corresponding alignment features on the applicator system 100 to ensure proper orientation and positioning during assembly. For example, in some embodiments, a protrusion on the substrate 116 may engage a corresponding hole on the applicator system 100, or a notch on the substrate 116 may engage a corresponding protrusion on the applicator system 100. In certain implementations, the alignment features are configured to guide relative movement between the substrate 116 and the applicator system 100 during coupling and / or actuation.
[0083] In some embodiments, the coupling interface 120 includes one or more locking mechanisms configured to secure the substrate 116 to the applicator system 100. The locking mechanisms may be configured for reversible locking, permitting disengagement of the substrate 116 from the applicator system 100, or irreversible locking, preventing separation after engagement. In certain embodiments, the locking mechanisms include snap-fit elements, interference features, detents, or similar mechanical retention structures. In some embodiments, the locking mechanisms are configured such that application of a force during actuation causes the substrate 116 to move relative to the applicator system 100 and engage or disengage one or more locking features.
[0084] In some embodiments, the coupling interface 120 is configured to position the substrate 116 and microneedle array 112 at a predetermined distance DI relative to a tissue surface prior to insertion. In certain embodiments, the applicator system 100 positions the substrate 116 such that the microneedle array 112 is spaced from the tissue surface by the predetermined distance DI prior to application of force. In some instances, the coupling interface 120 positions the substrate 116 atATTORNEY DOCKET NO. STFD-037-PCT PATENTa distance of about 1 mm or more from the tissue surface, such as about 1.5 mm or more, such as about 2 mm or more, such as about 2.5 mm or more, such as about 3 mm or more, such as about 3.5 mm or more, such as about 4 mm or more, such as about 4.5 mm or more, such as about 5 mm or more, such as about 5.5 mm or more, such as about 6 mm or more, such as about 6.5 mm or more, such as about 7 mm or more, such as about 7.5 mm or more, such as about 8 mm or more, such as about 8.5 mm or more, such as about 9 mm or more, such as about 9.5 mm or more, such as about 10 mm or more, such as about 15 mm or more, such as about 20 mm or more, such as about 25 mm or more, such as about 30 mm or more, such as about 40 mm or more, such as about 50 mm or more, such as about 100 mm or more, and including about 250 mm or more. The predetermined distance may be selected to control insertion depth of the microneedle array 112 following actuation of the applicator system 100.
[0085] When the applicator system 100 is coupled to the substrate 116, the structural elements 108 are configured to transmit the applied force through the coupling interface 120 to the substrate 116 and microneedle array 112. In some embodiments, the coupling interface 120 defines a load transfer region through which the applied force is transmitted. The load transfer region may be configured to distribute force uniformly across the substrate 116 or to concentrate force in selected regions, depending on the desired insertion characteristics. Following the mechanical transition of the structural elements 108, the load transfer through the coupling interface 120 may change to facilitate further advancement of the microneedle array 112 into tissue.
[0086] In some embodiments, the applicator system 100 and the microneedle array 112 are provided as separate components configured to be coupled prior to use. In other embodiments, the applicator system 100 and the substrate 116 are integrally formed as a single unit. In certain embodiments, the applicator system 100 is configured to be removably coupled to a plurality of different microneedle array substrates 116, allowing a single applicator system 100 to be used with multiple microneedle array configurations. In other embodiments, the applicator system 100 is configured for single-use operation and is permanently coupled to the substrate 116.
[0087] In certain embodiments, the applicator systems described herein may be configured to provide a multi-stage mechanical response in which two or more mechanical transitions occur at different applied force levels. Such configurations may enable staged insertion of a microneedle array and / or staged delivery or extraction of a bodily fluid.ATTORNEY DOCKET NO. STFD-037-PCT PATENT
[0088] In some embodiments, the structural elements 108 may include a first set of members and a second set of members. The first set of members and the second set of members may be arranged between the body 104 and the substrate 116 and may be configured to transmit force along one or more load paths to the microneedle array 112.
[0089] In some embodiments, the first set of members is configured to undergo a mechanical transition at a first force threshold, and the second set of members is configured to undergo a mechanical transition at a second force threshold. The second force threshold may be greater than the first force threshold, such that the first set of members transitions prior to the second set of members during application of force.
[0090] In certain embodiments, the first set of members and the second set of members may differ in one or more structural characteristics, including geometry, material composition, cross-sectional area, or length, such that the respective force thresholds are different. For example, the first set of members may include members having a smaller cross-sectional area or different geometry relative to the second set of members, resulting in a lower force required to initiate the mechanical transition.
[0091] In operation, a force applied to the body 104 is transmitted through the structural elements 108 toward the substrate 116 and microneedle array 112. As the applied force increases, the first set of members may undergo a first mechanical transition at the first force threshold. Continued application of force may then result in the second set of members undergoing a second mechanical transition at the second force threshold.
[0092] In some embodiments, the sequential mechanical transitions may correspond to staged insertion of the microneedle array 112 into tissue. For example, the first mechanical transition may facilitate initial penetration of the microneedle array 112 into a first tissue layer, and the second mechanical transition may facilitate further advancement into a second tissue layer.
[0093] In certain embodiments, the multi-stage mechanical response may be used to control insertion depth of the microneedle array 112. By configuring the first and second force thresholds appropriately, the applicator system 100 may be configured to provide a controlled insertion profile with reduced variability across users.
[0094] In some embodiments, the multi-stage mechanical response may be used in conjunction with delivery or extraction of a fluid. For example, a first mechanical transition may correspond to insertion of the microneedle array 112 into tissue, and a second mechanical transition mayATTORNEY DOCKET NO. STFD-037-PCT PATENTcorrespond to activation of a fluid transfer process, such as release of a fluid from a reservoir or collection of a biological fluid into a storage region.
[0095] In certain embodiments, one or more of the mechanical transitions described herein may include controlled fracture or separation of one or more structural elements, such as members within the structural elements 108. For example, a first force threshold may correspond to initial deformation or partial fracture to facilitate insertion of the microneedle array 112, while a second force threshold may correspond to further fracture or detachment of one or more structural components. In some embodiments, the second mechanical transition is associated with activation of a secondary function, such as initiation of fluid transfer (e.g., release of an active agent from a reservoir or collection of a biological fluid). In certain implementations, fracture of the structural elements 108 at or beyond the second threshold may produce a permanent structural change, such as breakage of a portion of the body 104 from the system 100, that provides a user-perceptible indication that the applicator system 100 has been actuated and / or used. In some embodiments, additional force thresholds may be defined, including a third threshold corresponding to release or disengagement of at least a portion of the applicator system from the tissue surface following use.
[0096] In certain embodiments, the structural elements 108 may include more than two sets of members, such that three or more sequential mechanical transitions may occur at increasing force thresholds. The number of stages and corresponding force thresholds may be selected based on the intended application of the applicator system 100.
[0097] In some embodiments, the members may be arranged in concentric, layered, or otherwise spatially distinct configurations relative to the body 104 and substrate 116. In other embodiments, the members may be interleaved or distributed throughout the structural elements 108.
[0098] In certain embodiments, the applicator system 100 may be configured such that each mechanical transition produces a user-perceptible indication, such as an audible or tactile signal, thereby indicating progression through the stages of actuation.
[0099] In some embodiments, one or more of the mechanical transitions may be irreversible, while in other embodiments one or more transitions may be reversible or partially reversible, depending on the configuration of the structural elements.
[0100] Referring to FIGS. 20A-20B, an applicator system 1000 according to another embodiment of the present disclosure is disclosed. The applicator system 1000 includes a body 1004 and one or more structural elements 1008 operably coupled to the body 1004. The structural elements 1008ATTORNEY DOCKET NO. STFD-037-PCT PATENTmay be configured to transmit an applied force from the body 1004 to a microneedle array 1012 (not depicted). The microneedle array 1012 may be supported on or coupled to a substrate 1016 (not depicted), such that the applied force is delivered along a defined load path from the body 1004, through the structural elements 1008, and to the substrate 1016 and microneedle array 1012.
[0101] In the illustrated embodiment, the structural elements 1008 comprise one or more breakable or compliant connections configured to undergo a mechanical transition when the applied force reaches a predetermined force threshold. The occurrence of the mechanical transition may result in a change in stiffness, resistance, or load transfer characteristics of the applicator system 1000, thereby facilitating insertion of the microneedle array 1012 into the tissue.
[0102] In some embodiments, the applicator system 1000 is configured such that the mechanical transition occurs at a predetermined force threshold that is defined by one or more properties of the structural elements 1008, including geometry, material composition, and / or dimensional characteristics. By configuring the structural elements 1008 to transition at the predetermined force threshold, the applicator system 1000 can provide controlled and repeatable insertion of the microneedle array 1012 independent of user variability.
[0103] In certain implementations, the mechanical transition of the structural elements 1008 is irreversible, such that once the predetermined force threshold is reached and the transition occurs, the applicator system 1000 is configured for single-use operation. In other implementations, the mechanical transition may be partially or fully reversible, depending on the configuration of the structural elements 1008.
[0104] In some embodiments, the applicator system 1000 may be configured to provide a user-perceptible indication when the mechanical transition occurs. For example, the transition may generate an audible, tactile, or visual indication associated with a change in structural state of the structural elements 1008, thereby signaling that sufficient force has been applied for insertion of the microneedle array 1012. In some embodiments, after the mechanical transition occurs, the visual indication is exposure of a color, such as red, which is on edge of the body and covered by the collar before a first threshold force is applied to the applicator, In some embodiments, upon mechanical transition and with a first threshold force applied, the collar physically separates from the body as the structural elements rupture, exposing the visual indicator, thereby signaling to a user that the microneedle array has been used and should not be re-used.ATTORNEY DOCKET NO. STFD-037-PCT PATENT
[0105] The applicator system 1000 may be configured as a standalone device or may be configured to be coupled to the microneedle array 1012 and substrate 1016 to form an integrated assembly. In some embodiments, the applicator system 1000 includes a coupling interface configured to engage the substrate 1016. The coupling interface may be configured for reversible or irreversible coupling and may include one or more alignment features configured to position the microneedle array 1012 relative to a tissue surface prior to insertion.
[0106] In operation, a user may apply a force to the body 1004 of the applicator system 1000, causing the force to be transmitted through the structural elements 1008 toward the microneedle array 1012. As the applied force increases and reaches the predetermined force threshold, the structural elements 1008 undergo the mechanical transition, resulting in insertion of the microneedle array 1012 into the tissue to a controlled depth.
[0107] Continuing with FIGS. 20A and 20B, the applicator system 1000 may be configured to facilitate controlled insertion of the microneedle array 1012 into biological tissue through a force-regulated mechanical response. The applicator system 1000 includes the body 1004 and one or more structural elements 1008 operably coupled to the body 1004. The structural elements 1008 may be configured to transmit an applied force from the body 1004 to the microneedle array 1012 supported on the substrate 1016.
[0108] The body 1004 comprises a support structure configured to be engaged by a user to apply a force to the applicator system 1000. In the illustrated embodiment, the body 1004 includes a proximal portion 1024 configured for user contact and a distal portion 1028 configured to interface with the structural elements 1008. The proximal portion 1024 is coupled to the distal portion 1028 via the one or more structural elements 1008. In some embodiments, a bottom portion of the proximal portion 1024 may be coupled to a top portion of the distal portion 1028 via the structural elements 1008.
[0109] In the illustrated embodiment, the proximal portion 1024 includes a recessed or depressed surface region 1030 configured to receive a finger and / or thumb of a user during application of force to the applicator system 1000. In some embodiments, the recessed or depressed surface region 1030 facilitates centering and distribution of the applied force along a substantially axial direction of the applicator system 1000.
[0110] In some embodiments, the distal portion 1028 comprises a collar structure configured to surround, engage, support, align, and / or interface with the substrate 1016 and / or microneedle arrayATTORNEY DOCKET NO. STFD-037-PCT PATENT1012. Tn certain embodiments, the distal portion 1028 comprises a substantially annular collar configured to remain positioned against a tissue surface and / or microneedle array assembly during actuation of the applicator system 1000.
[0111] The body 1004 may define one or more internal features, including cavities, guide surfaces, or support structures, configured to direct and distribute the applied force to the structural elements 1008. In certain embodiments, the body 1004 is substantially rigid to ensure that deformation of the applicator system 1000 occurs primarily within the structural elements 1008 rather than the body 1004.
[0112] The structural elements 1008 are configured to transmit force from the body 1004 to the substrate 1016 and microneedle array 1012 and to undergo a mechanical transition at a predetermined force threshold. In some embodiments, the structural elements 1008 comprise a plurality of members 1032 extending between the proximal portion 1024 and the distal portion 1028. As previously described, the members 1032 may comprise one or more of a strut, beam, membrane, bar, truss, or combination thereof. In certain embodiments, the structural elements 1008 include a plurality of members 1032 configured as struts.
[0113] In the illustrated embodiment, the structural elements 1008 include eight members 1032 circumferentially distributed around the body 1004. In some embodiments, the members 1032 are substantially equally spaced around the circumference of the body 1004.
[0114] Each member 1032 may define a cross-sectional geometry selected to achieve a desired mechanical response. In some embodiments, the members 1032 have a cross-sectional area of from 0.1 mm2to 1 mm2, such as from 0.15 mm2to 0.95 mm2, such as from 0.20 mm2to 0.90 mm2, such as from 0.25 mm2to 0.85 mm2, such as from 0.30 mm2to 0.80 mm2, such as from 0.35 mm2to 0.75 mm2, and including from 0.40 mm2to 0.70 mm2. In some instances, the cross-sectional area is from 0.12 mm2to 0.56 mm2. In some embodiments, one or more members 1032 include preweakened regions configured to localize stress and initiate a mechanical transition. The preweakened regions may include reduced cross-sectional regions, notches, perforations, or other stress concentrators. The number, arrangement, and geometry of the members 1032 may be selected collectively to define a desired force-displacement response of the applicator system 1000.
[0115] In some embodiments, the applicator system 1000 comprises a rigid component and a compliant component, wherein the rigid component maintains structural integrity and theATTORNEY DOCKET NO. STFD-037-PCT PATENTcompliant component includes the structural elements 1008 configured to undergo the mechanical transition.
[0116] The structural elements 1008 are configured to undergo a mechanical transition in response to an applied force. In the illustrated embodiment, the mechanical transition comprises complete fracture or breakage of the one or more members 1032 of the structural elements 1008 from the body 1004 such that the proximal portion 1024 and the distal portion 1028 are completely separated from each other.
[0117] In the illustrated embodiment, application of force to the proximal portion 1024 causes all eight members 1032 to fracture such that the distal portion 1028 completely separates from the proximal portion 1024, as shown in FIG. 20B. In some embodiments, all eight members 1032 fracture substantially simultaneously during application of the force.
[0118] In other embodiments, the mechanical transition comprises elastic deformation, plastic deformation, buckling, compression, expansion, or combinations thereof. The mechanical transition may result in a change in resistance to further displacement of the body 1004. For example, the applicator system 1000 may exhibit a first resistance to displacement prior to the transition and a reduced resistance after the transition, thereby facilitating insertion of the microneedle array 1012.
[0119] In some embodiments, the mechanical transition is irreversible, such that the members 1032 do not return to their original configuration after the transition. In other embodiments, the transition may be partially or fully reversible. In certain embodiments, the mechanical transition results in displacement of one or more portions of the applicator system 1000 in one or more directions, including along an X-axis, Y-axis, Z-axis, or combinations thereof. The displacement may correspond to a magnitude of 0.001 mm or more, such as 0.005 mm or more, such as 0.01 mm or more, such as 0.05 mm or more, such as 0.1 mm or more, such as 0.5 mm or more, such as 1 mm or more, such as 2 mm or more, such as 3 mm or more, such as 4 mm or more, such as 5 mm or more, such as 10 mm or more, such as 15 mm or more, such as 20 mm or more, and including 50 mm or more.
[0120] The structural elements 1008 are configured such that the mechanical transition occurs when the applied force reaches a predetermined force threshold. In some embodiments, the members 1032 are configured to break under an applied force of from about 5 N to about 250 N, such as from about 10 N to about 245 N, such as from 15 N to about 240 N, such as from about 20ATTORNEY DOCKET NO. STFD-037-PCT PATENTN to about 235 N, such as from about 25 N to about 230 N, such as from about 30 N to about 225 N, such as from about 35 N to about 220 N, such as from about 40 N to about 215 N, such as from about 45 N to about 210 N, such as from about 50 N to about 200 N, such as from about 75 N to about 175 N, such as from about 100 N to about 150 N, and including from about 10 N to about 170 N.
[0121] In some embodiments, the predetermined force threshold is defined by one or more of: a geometry of the members 1032, a material composition of the members 1032, and a dimensional characteristic of the members 1032. The predetermined force threshold may be selected to correspond to a force sufficient to insert the microneedle array 1012 into tissue to a desired depth, thereby reducing variability in insertion performance across users.
[0122] The structural elements 1008 define a load path extending from the body 1004 to the substrate 1016 and microneedle array 1012. The load path may be configured to transmit force along a substantially axial direction relative to the microneedle array 1012. In some embodiments, the members 1032 distribute the applied force across the substrate 1016. In other embodiments, the load path may be configured to concentrate force in selected regions. Following the mechanical transition, the load path may change such that the force is transmitted more directly from the body 1004 to the sub strate 1016.
[0123] In use, a user applies a mechanical force to the proximal portion 1024 of the body 1004. The applied force is transmitted through the structural elements 1008 toward the microneedle array 1012. As the applied force reaches the predetermined force threshold, the structural elements 1008 undergo the mechanical transition, resulting in insertion of the microneedle array 1012 into tissue. In some embodiments, the mechanical transition produces a user-perceptible indication, including an audible, tactile, or visual signal. The applicator system 1000 may be configured such that the mechanical transition occurs only once during use. Following the mechanical transition, continued application of force may result in further displacement of the body 1004 with reduced resistance, corresponding to advancement of the microneedle array 1012 into the tissue.
[0124] Referring to FIG. 5, an applicator system 200 is illustrated according to certain embodiments. The applicator system 200 may include a body 204, one or more structural elements 208, and a substrate 216 supporting a microneedle array 212. The applicator system 200 is configured to facilitate insertion of the microneedle array 212 into tissue in a manner similar to the applicator system 100 described above.ATTORNEY DOCKET NO. STFD-037-PCT PATENT
[0125] In the illustrated embodiment, the applicator system 200 further includes a distal or collar portion 224 extending from the body 204. The collar portion 224 is configured to surround at least a portion of the substrate 216 and / or microneedle array 212. In some embodiments, the collar portion 224 defines a peripheral boundary that constrains lateral movement of the substrate 216 relative to the body 204. The collar portion 224 may define an opening 228 through which the microneedle array 212 extends. The opening 228 may be sized and shaped to permit passage of the microneedle array 212 while maintaining alignment between the applicator system 200 and the substrate 216.
[0126] In certain embodiments, the collar portion 224 is configured to contact a tissue surface prior to insertion of the microneedle array 212. The collar portion 224 may thereby act as a positioning feature to stabilize the applicator system 200 and define a reference plane relative to the tissue surface.
[0127] The structural elements 208 are operably coupled between the body 204 and the substrate 216 and are configured to transmit an applied force from the body 204 to the substrate 216. As described with respect to the applicator system 100, the structural elements 208 may include a plurality of members 232 configured to undergo a mechanical transition at a predetermined force threshold.
[0128] In operation, a force applied to the body 204 is transmitted through the structural elements 208 to the substrate 216. Upon reaching the predetermined force threshold, the structural elements 208 undergo a mechanical transition, thereby facilitating insertion of the microneedle array 212 into the tissue. The collar portion 224 may maintain alignment and positioning of the applicator system 200 during this process.
[0129] In certain embodiments, the collar portion 224 and / or one or more of the structural elements 208 are configured to undergo controlled fracture upon application of force exceeding one or more predetermined thresholds. For example, the structural elements 208 may be configured such that fracture of the plurality of members 232 occurs after insertion of the microneedle array 212 and / or during a subsequent stage of actuation, thereby causing at least a portion of the collar portion 224 to detach, loosen, or otherwise change configuration relative to the body 204 and substrate 216. In some embodiments, this fracture is irreversible and serves as a tamper-evident or single-use indicator, providing a visual and / or tactile indication that the applicator system 200 has been used. In certain implementations, detachment or breakage of the collar portion 224 reduces theATTORNEY DOCKET NO. STFD-037-PCT PATENTlikelihood of reuse and thereby mitigates potential biohazard risks associated with repeated application. In some embodiments, the collar portion 224 may remain intact during initial insertion and depth control but fracture upon reaching a third or subsequent force threshold associated with completion of the procedure or disengagement of the device from the tissue surface.
[0130] In some embodiments, the collar portion 224 further functions to limit the depth of insertion of the microneedle array 212 by contacting the tissue surface and restricting further movement of the body 204 toward the tissue. In this manner, the collar portion 224 may cooperate with the structural elements 208 to provide controlled insertion of the microneedle array 212. The collar portion 224 may be integrally formed with the body 204 or may be provided as a separate component coupled to the body 204. The collar portion 224 may comprise a rigid or semi-rigid material configured to maintain structural integrity during application of force.
[0131] Referring to FIGS. 6 and 7, an applicator system 300 is illustrated according to certain embodiments. The applicator system 300 may include a body 304, one or more structural elements 308, and a microneedle array 312 supported on a substrate 316. In contrast to the applicator systems described above, the applicator system 300 may be configured as an integrated structure in which the body 304 and the substrate 316 are formed as a single unit. In certain embodiments, the substrate 316 is integrally formed with the body 304 such that a separate coupling interface is not required. The microneedle array 312 may extend from a distal surface 320 of the integrated structure, and the structural elements 308 may be disposed between a proximal portion 324 of the body 304 and the distal surface 320.
[0132] In certain embodiments, the body 304 may define a non-uniform internal geometry between the proximal portion 324 and the distal surface 320. For example, one or more portions of the body 304 may be inclined or angled relative to a longitudinal axis of the applicator system 300, such that an applied force is directed along a non-linear load path toward the microneedle array 312. The structural elements 308 may extend between these portions of the body 304 and the distal surface 320, thereby transmitting force through the integrated structure in a controlled manner.
[0133] The structural elements 308 are configured to transmit an applied force through the integrated structure to the microneedle array 312. In some embodiments, the structural elements 308 include a plurality of members 332 configured to undergo a mechanical transition at a predetermined force threshold, as described with respect to the applicator system 100.ATTORNEY DOCKET NO. STFD-037-PCT PATENT
[0134] In the integrated configuration, the load path extends directly from the body 304 through the structural elements 308 to the microneedle array 312 without an intermediate coupling interface. This configuration may reduce the number of components and eliminate relative motion between separately coupled parts. In some embodiments, the body 304 and substrate 316 are formed from a common material or are co-fabricated using a single manufacturing process. In other embodiments, the body 304 and substrate 316 may comprise different materials that are joined during fabrication to form the integrated structure.
[0135] The applicator system 300 may be configured such that the structural elements 308 are positioned within an interior region 328 of the body 304. In certain embodiments, the structural elements 308 are arranged to define a load-bearing network that distributes applied force across the microneedle array 312.
[0136] In operation, a force applied to the proximal portion 324 of the body 304 is transmitted through the structural elements 308 to the microneedle array 312. When the applied force reaches the predetermined force threshold, the structural elements 308 undergo the mechanical transition, thereby facilitating insertion of the microneedle array 312 into tissue.
[0137] In some embodiments, the integrated configuration of the applicator system 300 provides improved alignment between the structural elements 308 and the microneedle array 312, as relative positioning between separate components is eliminated. In certain embodiments, the integrated structure may be configured for single-use operation.
[0138] Referring to FIGS. 8-9, an applicator system 500 is illustrated according to certain embodiments. The applicator system 500 may include a body 504, one or more structural elements 508, and a microneedle array 512 supported on a substrate 516. The applicator system 500 is configured to facilitate insertion of the microneedle array 512 into tissue and to provide a reservoir structure for containing or transferring a fluid.
[0139] In certain embodiments, the applicator system 500 includes a reservoir 520 in fluid communication with the microneedle array 512. The reservoir 520 may be defined within the body 504, the substrate 516, or a combination thereof. The reservoir 520 may comprise a cavity or enclosed volume configured to store a fluid prior to, during, or after insertion of the microneedle array 512 into tissue.
[0140] In some embodiments, the reservoir 520 is configured to contain an active agent for delivery to a subject. In other embodiments, the reservoir 520 is configured to receive and retain aATTORNEY DOCKET NO. STFD-037-PCT PATENTbiological fluid collected from the tissue via the microneedle array 512. The reservoir 520 may be fluidically coupled to the microneedle array 512 through one or more channels 524 defined within the substrate 516 and / or body 504.
[0141] In certain embodiments, the channels 524 are configured to permit fluid transfer between the microneedle array 512 and the reservoir 520. The channels 524 may include one or more passages that provide fluid communication between the microneedle array 512 and the reservoir 520. In some embodiments, fluid transfer may occur passively, for example through capillary action or pressure gradients generated during insertion of the microneedle array 512 into the tissue.
[0142] In some embodiments, the applicator system 500 further includes a pump component 528 configured to facilitate movement of fluid between the reservoir 520 and the microneedle array 512. The pump component 528 may include an actuator element configured to be displaced relative to the body 504, such as a plunger or piston, to generate fluid flow through the channels 524. In certain embodiments, the actuator element is coupled to a fluid chamber defined within the body 504 and is configured such that displacement of the actuator element causes a change in volume within the fluid chamber, thereby driving fluid movement.
[0143] In some embodiments, the actuator element of the pump component 528 may extend into the body 504 through a side portion of the body 504 and may be configured for manual actuation. Displacement of the actuator element may cause fluid to be drawn from the microneedle array 512 into the reservoir 520 or, alternatively, to be conveyed from the reservoir 520 through the microneedle array 512 and into the tissue.
[0144] The structural elements 508 are operably coupled between the body 504 and the substrate 516 and are configured to transmit an applied force from the body 504 to the microneedle array 512. As described above, the structural elements 508 may include a plurality of members 532 configured to undergo a mechanical transition at a predetermined force threshold. In operation, a force applied to the body 504 is transmitted through the structural elements 508 to the substrate 516 and microneedle array 512, and upon reaching the predetermined force threshold, the structural elements 508 undergo the mechanical transition to facilitate insertion of the microneedle array 512 into the tissue.
[0145] In some embodiments, the reservoir 520 is configured to retain a volume of fluid following insertion of the microneedle array 512. The volume of the reservoir 520 may be selected based on the intended use of the applicator system 500. For example, the reservoir 520 may have a volumeATTORNEY DOCKET NO. STFD-037-PCT PATENTof 0.001 mL or more, such as 0.005 mL or more, such as 0.01 mL or more, such as 0.05 mL or more, such as 0.1 mL or more, such as 0.5 mL or more, such as 1 mL or more, such as 2 mL or more, such as 3 mL or more, such as 4 mL or more, such as 5 mL or more, such as 6 mL or more, such as 7 mL or more, such as 8 mL or more, such as 9 mL or more, such as 10 mL or more, such as 15 mL or more, such as 20 mL or more, such as 25 mL or more, and including 50 mL or more.
[0146] In certain embodiments, each microneedle of the microneedle array 512 may be fluidically coupled to a separate portion of the reservoir 520. In other embodiments, the reservoir 520 may comprise a single volume configured to receive fluid from a plurality of microneedles.
[0147] In further embodiments, the reservoir 520 and / or the pump component 528 may be integrated into the body 504 to form a unitary structure. In other embodiments, the reservoir 520 and / or pump component 528 may be provided as separate components configured to be coupled to the applicator system 500.
[0148] Referring to FIGS. 10A-10C, an applicator system 600 is illustrated according to certain embodiments. The applicator system 600 may include a body 604, one or more structural elements 608, and a microneedle array 612 supported on a substrate 616. The applicator system 600 is configured to facilitate insertion of the microneedle array 612 into tissue and to provide staged delivery of a fluid.
[0149] In certain embodiments, the applicator system 600 further includes a reservoir 620 configured to contain a fluid, such as a buffer or active agent. The reservoir 620 may be positioned within the body 604 and may be disposed above or adjacent to the microneedle array 612. The reservoir 620 may be separated from the microneedle array 612 prior to actuation.
[0150] In some embodiments, the structural elements 608 are configured to undergo a mechanical transition in response to an applied force. The structural elements 608 may include a plurality of members 632 configured to fracture, deform, or otherwise change configuration at one or more predetermined force thresholds.
[0151] In certain embodiments, the applicator system 600 is configured for multi-stage actuation. A first applied force may cause the microneedle array 612 to be inserted into tissue while the structural elements 608 remain at least partially intact. A second applied force, greater than the first force, may cause one or more of the structural elements 608 to undergo a mechanical transition, thereby enabling further movement of internal components of the applicator system 600.ATTORNEY DOCKET NO. STFD-037-PCT PATENT
[0152] In some embodiments, the mechanical transition of the structural elements 608 results in displacement of the reservoir 620 or an associated fluid chamber, thereby causing the fluid contained within the reservoir 620 to be delivered toward the microneedle array 612. The fluid may be conveyed into the microneedle array 612 and subsequently into the tissue.
[0153] In certain embodiments, the applicator system 600 includes one or more intermediate components 624 positioned between the reservoir 620 and the microneedle array 612. The intermediate components 624 may be configured to control the release of fluid, for example by acting as a barrier, valve, or rupturable membrane that is opened or displaced upon the mechanical transition of the structural elements 608.
[0154] In operation, the applicator system 600 may be positioned against a tissue surface and a force applied to the body 604. Upon application of a first force, the microneedle array 612 may be inserted into the tissue. Upon application of a second force, the structural elements 608 may undergo the mechanical transition, thereby enabling fluid from the reservoir 620 to be delivered through the microneedle array 612 into the tissue.
[0155] In some embodiments, the staged actuation of the applicator system 600 provides controlled delivery of the fluid following insertion of the microneedle array 612. This configuration may improve delivery efficiency and reduce variability by separating insertion and fluid delivery into distinct stages.
[0156] Referring to FIGS. 11-14, an applicator system 700 is illustrated according to certain embodiments. The applicator system 700 may include a body 704, one or more structural elements 708, and a microneedle array 712 supported on a substrate 716. The applicator system 700 is configured to facilitate insertion of the microneedle array 712 into tissue in a manner consistent with the applicator systems described herein.
[0157] In certain embodiments, the applicator system 700 comprises a base structure 720 defining an overall geometry of the device. The base structure 720 may include one or more external surfaces 724 configured to contact a tissue surface and stabilize the applicator system 700 during insertion. The base structure 720 may be configured with different geometric profiles, including variations in height, thickness, and lateral dimensions.
[0158] In some embodiments, the structural elements 708 include a plurality of members 732 configured to transmit force from the body 704 to the substrate 716. The members 732 may be arranged in a pattern that varies across embodiments, including differences in spacing, orientation,ATTORNEY DOCKET NO. STFD-037-PCT PATENTand connectivity. In certain embodiments, the arrangement of members 732 defines a repeating or non-repeating structural pattern across the applicator system 700.
[0159] In certain embodiments, the applicator system 700 includes one or more openings or cutout regions 728 formed within the base structure 720. The cutout regions 728 may be configured to reduce material usage, modify mechanical properties, or alter the force distribution within the applicator system 700. The size, shape, and distribution of the cutout regions 728 may vary across embodiments.
[0160] In some embodiments, the applicator system 700 may be provided in multiple configurations having different heights. For example, the base structure 720 may define a first height in a first embodiment and a second height in a second embodiment, where the second height is greater than or less than the first height. The variation in height may be selected to modify insertion depth, force response, or ergonomic characteristics of the applicator system 700.
[0161] In certain embodiments, the external surfaces 724 and / or base structure 720 may define a perimeter geometry selected from one or more of circular, rectangular, square, polygonal, or irregular shapes. The perimeter geometry may influence contact area with the tissue surface and overall stability of the applicator system 700 during use.
[0162] The structural elements 708 are configured to undergo a mechanical transition at a predetermined force threshold, as described with respect to the applicator system 100. In operation, a force applied to the body 704 is transmitted through the structural elements 708 to the substrate 716 and microneedle array 712, and upon reaching the predetermined force threshold, the structural elements 708 undergo the mechanical transition to facilitate insertion of the microneedle array 712 into the tissue.
[0163] In some embodiments, the geometric variations described herein may be implemented individually or in combination. For example, a given embodiment may include both cutout regions 728 and a modified height, or may include variations in both structural element arrangement and external geometry. The specific combination of features may be selected to achieve a desired mechanical response, insertion depth, or user interaction profile.
[0164] In some embodiments, the applicator systems described herein are configured for integration with additional microneedle-based delivery, sensing, sampling, monitoring, and fluidic device architectures. In certain instances, the applicator systems are configured to facilitate insertion of microneedle arrays into biological tissue prior to delivery of a fluidic medium,ATTORNEY DOCKET NO. STFD-037-PCT PATENTwithdrawal of a biological fluid sample, sensing, monitoring, or activation of an additional device component. In some embodiments, the biological tissue includes skin, mucosal tissue, organ tissue, tumor tissue, ocular tissue, vascular tissue, or combinations thereof.
[0165] FIG. 15A depicts one embodiment of an integrated applicator system 800 configured for use with a puncture-out-and-press (“POP”) device for interstitial fluid collection. As shown in FIG.15A, the applicator system 800 includes a microneedle array 802 configured to puncture a tissue surface 804 of a subject and create a plurality of puncture sites. Following insertion of the microneedle array 802 into tissue, the applicator system 800 is configured to transition from a puncture configuration to a pressing configuration in which a collection structure 806 is pressed against the tissue surface 804 to facilitate withdrawal of biological fluid, such as interstitial fluid, from the puncture sites.
[0166] In some embodiments, the applicator system 800 includes one or more structural elements 808 configured to fracture, deform, or otherwise undergo a mechanical transition upon application of a predetermined force. In certain instances, actuation of the applicator system 800 facilitates insertion of the microneedle array 802 into tissue prior to operation of the collection structure 806. In some embodiments, the applicator system 800 is configured such that puncturing, withdrawal, and pressing operations occur sequentially during a single application process.
[0167] FIG. 15B depicts another embodiment of the applicator system 800. In the embodiment shown in FIG. 15B, the applicator system 800 includes a support collar 822 configured to couple with a body component 824 and a microneedle module 826 including the microneedle array 802. In some instances, the support collar 822 includes one or more structural elements 832 configured to fracture, deform, or otherwise undergo a mechanical transition upon application of a threshold force.
[0168] In certain embodiments, the body component 824 includes one or more coupling structures 828 configured to engage the support collar 822. In some embodiments, the microneedle module 826 positioned within the body component 824 is configured for interstitial fluid collection, biological sensing, analyte detection, sampling, monitoring, or fluid delivery. In certain instances, the support collar 822 and body component 824 are configured to facilitate insertion of the microneedle module 826 into tissue upon activation of the tunable applicator mechanism.
[0169] In some embodiments, the support collar 822 includes a selected height and / or geometry relative to the body component 824 and microneedle module 826. Variation of the height of theATTORNEY DOCKET NO. STFD-037-PCT PATENTsupport collar 822 may alter the relative overlap between the support collar 822 and the body component 824 during application of force. In certain embodiments, partial overlap between the support collar 822 and the body component 824, such as illustrated in FIG. 15B, improves insertion consistency and puncture reliability by stabilizing the applicator system 800 and reducing off-axis movement during actuation.
[0170] In some embodiments, separating the support collar 822 and body component 824 facilitates assembly of complex microneedle-based systems. For example, the microneedle module 826 may be inserted into the body component 824 prior to coupling with the support collar 822 during manufacturing, assembly, sterilization, or fill-finish processing.
[0171] FIG. 15C depicts a further embodiment of the applicator system 840. In the embodiment shown in FIG. 15C, the applicator system 840 includes two or more tunable applicator stages configured to activate sequentially at different force thresholds.
[0172] In some embodiments, a first applicator stage 842 is configured to activate at a first threshold force and a second applicator stage 844 is configured to activate at a second threshold force greater than the first threshold force. In certain instances, the first applicator stage 842 facilitates insertion of one or more microneedles into tissue, while the second applicator stage 844 facilitates activation of a secondary function component, including but not limited to fluid delivery, fluid withdrawal, sensing activation, pumping, reservoir activation, valve opening, or mechanical deployment of an additional device component.
[0173] In some embodiments, sequential activation of the applicator stages 842, 844 is achieved through continuous application of force by a user. In certain instances, the multi-stage applicator system 840 provides a plurality of distinct mechanical transitions during a single actuation event.
[0174] In some embodiments, the integrated and multi-stage applicator architectures described herein provide simplified operation of microneedle-based systems while facilitating reliable insertion, fluidic operation, sensing, monitoring, sampling, or delivery functions.
[0175] In certain embodiments, the applicator systems described herein are configured for use with microneedle arrays that facilitate transdermal access to tissue. The microneedle arrays may be configured for delivery of a substance to a subject, extraction of a biological fluid from a subject, or both.
[0176] Referring generally to the microneedle array 112, 212, 312, 412, 512, 612, 712 the microneedle array may include a plurality of microneedles supported on the substrate 116, 216,ATTORNEY DOCKET NO. STFD-037-PCT PATENT316, 416, 516, 616, 712. The substrate may comprise a base structure configured to support the microneedles and interface with the applicator systems described herein. In some embodiments, the microneedle array includes 2 or more microneedles, such as 3 or more, such as 4 or more, such as 5 or more, such as 10 or more, such as 25 or more, such as 50 or more, such as 100 or more, such as 250 or more, such as 500 or more, and including 1000 microneedles or more.
[0177] In certain embodiments, the microneedles 1100 are arranged in an array pattern on the substrate. The microneedles may be arranged along one or more lines or in a geometric configuration selected from square, rectangular, trapezoidal, triangular, hexagonal, heptagonal, octagonal, nonagonal, decagonal, dodecagonal, circular, oval, or irregular configurations. In some embodiments, the microneedles are separated from each other by an average distance of from about 1 pm to about 1000 pm, such as from about 2 pm to about 950 pm, such as from about 3 pm to about 900 pm, such as from about 4 pm to about 850 pm, such as from about 5 pm to about 800 pm, such as from about 6 pm to about 750 pm, such as from about 7 pm to about 700 pm, such as from about 8 pm to about 650 pm, such as from about 9 pm to about 700 pm, such as from about 10 pm to about 550 pm, such as from about 15 pm to about 500 pm, such as from about 20 pm to about 450 pm, and including from about 25 pm to about 400 pm.
[0178] Each microneedle may define a three-dimensional structure extending from the substrate. The microneedles may include a length and a width selected based on the intended application.
[0179] In some embodiments, each microneedle has a length of from about 50 pm to about 2000 pm, such as from about 75 pm to about 1950 pm, such as from about 100 pm to about 1900 pm, such as from about 125 pm to about 1850 pm, such as from about 150 pm to about 1800 pm, such as from about 175 pm to about 1750 pm, such as from about 200 pm to about 1700 pm, such as from about 225 pm to about 1650 pm, such as from about 250 pm to about 1600 pm, such as from about 275 pm to about 1550 pm, and including from about 300 pm to about 1500 pm. In some embodiments, each microneedle has a width (or diameter) of from about 50 pm to about 1000 pm, such as from about 75 pm to about 950 pm, such as from about 100 pm to about 900 pm, such as from about 125 pm to about 850 pm, such as from about 150 pm to about 800 pm, such as from about 175 pm to about 750 pm, such as from about 200 pm to about 700 pm, such as from about 225 pm to about 650 pm, such as from about 250 pm to about 600 pm, such as from about 275 pm to about 550 pm, and including from about 300 pm to about 500 pm.ATTORNEY DOCKET NO. STFD-037-PCT PATENT
[0180] The microneedles may have any suitable shape, including rectilinear cross-sectional shapes (e g., square, rectangular, trapezoidal, triangular, hexagonal), curvilinear shapes (e.g., circular or oval), or irregular geometries.
[0181] In some embodiments, the microneedles include a lattice microstructure. The lattice microstructure may comprise a network of interconnected structural elements defining internal void spaces within the microneedle. In certain embodiments, the lattice microstructure includes a plurality of repeating lattice cell units. The number of lattice cell units may be 2 or more, such as 3 or more, such as 4 or more, and including 5 or more. In some embodiments, the lattice cell units have a shape selected from tetrahedral, Kagome, rhombic, icosahedral, Voronoi, triangular, or combinations thereof. In certain embodiments, the lattice microstructure is formed from lattice cells having a unit size of from about 1 pm to about 1000 pm, such as from about 5 pm to about 950 pm, such as from about 10 pm to about 900 pm, such as from about 1 pm to about 850 pm, such as from about 20 pm to about 800 pm, such as from about 25 pm to about 750 pm, such as from about 30 pm to about 700 pm, such as from about 35 pm to about 650 pm, such as from about 40 pm to about 600 pm, such as from about 45 pm to about 550 pm, and including from about 50 pm to about 500 pm.
[0182] In some embodiments, the lattice microstructure includes a plurality of struts having a thickness of from about 1 pm to about 200 pm, such as from about 2 pm to about 190 pm, such as from about 3 pm to about 180 pm, such as from about 4 pm to about 170 pm, such as from about 5 pm to about 160 pm, such as from about 6 pm to about 150 pm, such as from about 7 pm to about 140 pm, such as from about 8 pm to about 130 pm, such as from about 9 pm to about 120 pm, and including from about 10 pm to about 100 pm.
[0183] In some embodiments, the lattice microstructure defines a volume of from about 0.01 pL to about v25 pL, such as from 0.02 pL to 24.5 pL, such as from 0.03 pL to 24 pL, such as from 0.04 pL to 23.5 pL, such as from 0.05 pL to 23 pL, such as from 0.6 pL to 22.5 pL, such as from 0.07 pL to 22 pL, such as from 0.08 pL to 21.5 pL, such as from 0.09 pL to 21 pL, such as from 0.1 pL to 20 pL, such as from 0.5 pL to 19 pL, such as from about 1 pL to about 18 pL, such as from 2 pL to 17 pL, such as from 3 pL to 16 pL, and including from about 4 pL to about 15 pL.
[0184] In certain embodiments, the lattice microstructure has a uniform density. In other embodiments, the density of lattice cell units varies across the microneedle. In some embodiments, the density of lattice cell units increases along a longitudinal axis of the microneedle. The increaseATTORNEY DOCKET NO. STFD-037-PCT PATENTin density may be 1% or more, such as 2% or more, such as 3% or more, such as 4% or more, such as 5% or more, such as 10% or more, such as 20% or more, such as 30% or more, such as 40% or more, and including 50% or more. The density variation may occur at predetermined increments along the microneedle, such as every 1 pm or more, such as every 2 pm or more, such as every 3 pm or more, such as every 4 pm or more, such as every 5 pm or more, such as every 10 pm or more, such as every 20 pm or more, such as every 30 pm or more, such as every 40 pm or more, and including every 50 pm or more.
[0185] In some embodiments, each microneedle includes a plurality of regions defining different structural characteristics along its length. For example, a microneedle may include a tip section, a body section, and a base section extending from the substrate. The tip section may be configured to facilitate penetration of tissue and may comprise a solid structure to provide mechanical strength and reduce the likelihood of fracture during insertion. In certain embodiments, the tip section has a length of from 10 pm to 500 pm, such as from 20 pm to 490 pm, such as from 30 pm to 480 pm, such as from 40 pm to 470 pm, such as from 50 pm to 460 pm, such as from 60 pm to 450 pm, such as from 70 pm to 440 pm, such as from 80 pm to 430 pm, such as from 90 pm to 420 pm, such as from 100 pm to 410 pm, such as from 110 pm to 400 pm, such as from 120 pm to 390 pm, such as from 130 pm to 380 pm, such as from 140 pm to 370 pm, and including from 150 pm to 360 pm.
[0186] The body section may extend proximally from the tip section and, in some embodiments, includes a lattice microstructure as described above. The lattice structure of the body section may provide a balance between mechanical integrity and internal void volume, enabling both structural support and fluid transport or storage. In certain embodiments, the body section has a length selected based on the intended insertion depth and functional requirements of the microneedle, including configurations in which the body section defines a majority of the microneedle length.
[0187] The base section may be positioned between the body section and the substrate and may comprise a solid or partially solid structure configured to provide mechanical support and secure attachment of the microneedle to the substrate. In some embodiments, the base section may have dimensions selected to enhance stability during insertion and to distribute mechanical loads applied by the applicator system.
[0188] In certain embodiments, one or more of the tip section, body section, and base section may be solid, hollow, or include a lattice microstructure. For example, in some configurations, the tipATTORNEY DOCKET NO. STFD-037-PCT PATENTsection and base section are solid while the body section includes a lattice microstructure. In other configurations, the microneedle may include a hollow interior or a fully lattice-based structure along its length.
[0189] In some embodiments, the microneedles are configured to exhibit a degree of compliance and may undergo elastic deformation under load. The degree of deformation may depend on the material properties and structural configuration of the microneedle, including whether the microneedle includes lattice features or solid regions. Such compliance may be selected to reduce fracture risk during insertion and to improve interaction with tissue.
[0190] In certain embodiments, the microneedle arrays described herein may be configured for delivery of a substance to a subject, extraction of a biological fluid from a subject, or both. The microneedle arrays may be used in conjunction with the applicator systems described herein to facilitate controlled transdermal access to tissue, including but not limited to applicator systems 100, 400, 500, and 600 illustrated in FIGS. 1-10C.
[0191] In some embodiments, the microneedle arrays are configured to deliver a substance to a subject through one or more microneedles, such as in delivery-focused embodiments including lattice micro-array patch systems (e.g., system 600 shown in FIGS. 10A-10C). In other embodiments, the microneedle arrays are configured to extract a biological fluid from a subject, such as interstitial fluid, dermal fluid, or blood, including in interstitial fluid collection embodiments.
[0192] In certain embodiments, the microneedles are configured to form one or more micro-scale openings in the tissue upon insertion, thereby enabling transport of a fluid across a tissue boundary. The transport of fluid may occur passively, for example through capillary action (e.g., within lattice microstructures of system 600), or may occur in response to pressure gradients generated during insertion of the microneedles or through applied vacuum or pumping mechanisms (e.g., systems 400 and 500).
[0193] In some embodiments, the microneedles are configured to collect 0.01 pL or more of biological fluid, such as 0.05 pL or more, such as 0.1 pL or more, such as 0.2 pL or more, such as 0.3 pL or more, such as 0.4 pL or more, such as 0.5 pL or more, such as 1 pL or more, such as 2 pL or more, such as 3 pL or more, such as 4 pL or more, such as 5 pL or more, and including 10 pL or more, including in fluid collection embodiments such as system 400.ATTORNEY DOCKET NO. STFD-037-PCT PATENT
[0194] In certain embodiments, biological fluid may be collected over a period of time of about 1 second or more, such as about 5 seconds or more, such as 10 seconds or more, such as 15 seconds or more, such as about 30 seconds or more, such as about 1 minute or more, such as about 5 minutes or more, such as about 10 minutes or more, such as about 15 minutes or more, such as about 30 minutes or more, such as about 1 hour or more, such as about 2 hours or more, such as about 3 hours or more, such as about 6 hours or more, such as 12 hours or more, such as about 18 hours or more, and including about 24 hours or more, for example during application of a fluid collection device (e.g., system 400) or a wearable patch configuration.
[0195] In certain embodiments, the microneedle arrays may be placed in fluid communication with one or more reservoirs. The reservoirs may be configured to contain a substance for delivery to a subject or to collect a biological fluid extracted from a subject, including in embodiments incorporating integrated reservoirs (e.g., reservoir 520 of system 500 shown in FIGS. 8-9).
[0196] In some embodiments, a reservoir 520 may have a volume of about 0.001 mL or more, such as 0.005 mL or more, such as 0.01 mL or more, such as 0.05 mL or more, such as 0.1 mL or more, such as 0.5 mL or more, such as about 1 mL or more, such as about 2 mL or more, such as about 3 mL or more, such as about 4 mL or more, such as about 5 mL or more, such as about 6 mL or more, such as about 7 mL or more, such as about 8 mL or more, such as about 9 mL or more, such as about 10 mL or more, such as about 15 mL or more, such as about 20 mL or more, such as about 25 mL or more, and including about 50 mL or more, such as in integrated reservoir embodiments (e.g., system 500).
[0197] In certain embodiments, each microneedle may be fluidically coupled to a separate reservoir, or multiple microneedles may share a common reservoir. Fluid communication between the microneedles and the reservoir may be achieved through one or more channels formed within the substrate or applicator system, including channels integrated within devices such as systems 500 and 600.
[0198] In some embodiments, a pump component may be included to facilitate movement of fluid between the reservoir and the microneedles. The pump component may be configured to draw fluid into the reservoir or to deliver fluid from the reservoir through the microneedles, such as in embodiments including integrated pumping systems (e.g., system 500).
[0199] In certain embodiments, the microneedles may include an active agent compound. The active agent compound may be configured for delivery into tissue following insertion of theATTORNEY DOCKET NO. STFD-037-PCT PATENTmicroneedles, including in delivery-focused embodiments such as lattice micro-array patch systems (e.g., system 600).
[0200] In some embodiments, the active agent compound is coated onto one or more surfaces of the microneedles. In some instances, the active agent compound is coated onto a tip section, a body section, or a base section of the microneedles. In other embodiments, the active agent compound is contained within a lattice microstructure of the microneedles, such as in lattice-based delivery embodiments (e.g., system 600 shown in FIGS. 10A-10C).
[0201] In some embodiments, the active agent compound fills 1% or more of the void volume of a lattice microstructure, such as 2% or more, such as 3% or more, such as 4% or more, such as 5% or more, such as 6% or more, such as 7% or more, such as 8% or more, such as 9% or more, such as 10% or more, such as 15% or more, such as 20% or more, such as 25% or more, and including 50%> or more, such as in lattice-based microneedles (e.g., system 600).
[0202] In some embodiments, each microneedle contains 0.01 pL or more of the active agent compound, such as 0.05 pL or more, such as 0.1 pL or more, such as 0.2 pL or more, such as 0.3 pL or more, such as 0.4 pL or more, such as 0.5 pL or more, such as 1 pL or more, such as 2 pL or more, such as 3 pL or more, such as 4 pL or more, such as 5 pL or more, and including 10 pL or more, including in embodiments utilizing lattice storage and delivery (e.g., system 600).
[0203] The active agent compounds described herein may be used in any of the delivery embodiments disclosed, including but not limited to lattice-based delivery systems (e.g., system 600) and reservoir-based delivery systems (e.g., system 500). The active agent compound may include, but is not limited to, organic materials such as enzymes, nucleic acids, peptides, proteins, antibodies, hormones, growth factors, small molecules, lipids, carbohydrates, and combinations thereof.
[0204] In some embodiments, the active agent compound may include an immunogenic substance such as a vaccine. The vaccine may be selected from a wide range of commercially available or investigational vaccines.
[0205] In certain embodiments, the active agent compound includes small molecule drugs, including but not limited to analgesics, anti-inflammatory agents, antibiotics, antivirals, antifungal agents, chemotherapeutic agents, and combinations thereof.
[0206] In some embodiments, the active agent compound may include one or more excipients, such as stabilizers, binders, preservatives, or buffering agents.ATTORNEY DOCKET NO. STFD-037-PCT PATENT
[0207] In certain embodiments, the microneedles are configured to release the active agent compound upon insertion into tissue. In other embodiments, the microneedles are configured to release the active agent compound over a period of time.
[0208] In some embodiments, the active agent compound may be released over a period of about 0.01 hours or more, such as about 0.05 hours or more, such as about 0.1 hours or more, such as about 0.5 hours or more, such as about 1 hour or more, such as about 2 hours or more, such as about 6 hours or more, such as about 12 hours or more, such as about 18 hours or more, such as about 24 hours or more, such as about 36 hours or more, such as about 48 hours or more, such as about 72 hours or more, such as about 96 hours or more, such as about 120 hours or more, such as about 144 hours or more, and including about 168 hours or more.
[0209] In certain embodiments, the active agent compound may be delivered over a period of from about 1 minute to about 6 months, including shorter and longer durations as appropriate for the intended application.
[0210] In certain embodiments, the active agent compound may comprise a wide variety of biologically active materials. The active agent compound may include, but is not limited to, organic materials such as horseradish peroxidase, phenolsulfonphthalein, nucleotides, nucleic acids (e.g., oligonucleotides, polynucleotides, siRNA, shRNA), aptamers, antibodies or portions thereof (e.g., antibody-like molecules), hormones (e.g., insulin, testosterone), growth factors, enzymes (e.g., peroxidase, lipase, amylase, organophosphate dehydrogenase, ligases, restriction endonucleases, ribonucleases, RNA or DNA polymerases, glucose oxidase, lactase), cells (e.g., red blood cells, stem cells), bacteria or viruses, other proteins or peptides, small molecules (e.g., drugs, dyes, amino acids, vitamins, antioxidants), lipids, carbohydrates, chromophores, light emitting organic compounds (such as luciferin, carotenes) and light emitting inorganic compounds (e.g., chemical dyes and / or contrast enhancing agents such as indocyanine green), immunogenic substances such as vaccines, antibiotics, antifungal agents, antiviral agents, therapeutic agents, diagnostic agents or pro-drugs, analogs or combinations of any of the foregoing.
[0211] In certain embodiments, the active agent compound may include an immunogenic substance such as a vaccine. Examples of immunogenic vaccine substances that can be included in the microneedles described herein include, but are not limited to, those in BIOTHRAX® (anthrax vaccine adsorbed); TICE® BCG Live (Bacillus Calmette-Guerin); MYCOBAX® BCG Live; DAPTACEL® (diphtheria and tetanus toxoids and acellular pertussis vaccine);ATTORNEY DOCKET NO. STFD-037-PCT PATENTINFANRIX®; TRIPEDIA®; TRIHIBIT®; KINRIX®; PEDIARIX®; PENTACEL®; diphtheria and tetanus toxoids vaccines; DECAV AC®; ACTHIB®; PEDVAXHIB®; Hiberix®; COMV AX®; HAVRIX®; VAQTA®; ENGERIX-B®; RECOMBIVAX HB®; TWINRIX®; CERVARIX®; GARDASIL®; AFLURIA®; AGRIFLU™; FLUARIX®; FLULAVAL®; FLUVIRIN®; FLUZONE®; FLUMIST®; IPOL®; JE VAX®; IXIARO®; MENACTRA®; MENOMUNE®; MMRII®; MENVEO®; PROQUAD®; PNEUMO VAX 23®; PREVNAR®; PREVNAR- 13®; POLIO VAX™; IMO VAX®; RAB AVERT™; ROTATEQ®; ROTARIX®; Td vaccines; TYPHIM VI®; ADACEL®; BOOSTRIX®; VIVOTIF®; ACAM2000™; DRYVAX®; VARIVAX®; YF-VAX®; ZOSTAVAX®; or combinations thereof. Any vaccine products listed in databases such as those of the Centers for Disease Control and Prevention (CDC) may also be included. The disclosure therefore relates to methods of vaccinating a subject in need thereof comprising administering to the subject a therapeutically or prophylactically effective amount of one or a combination of two or more active agents that are antigens integrated within the microneedle array. In some embodiments, the antigen is a viral antigen or cancer antigen. In some embodiments, the viral antigens are antigens from diptheria, tetanus, influenza, HPV, hepatitis A, hepatitis B, hepatitis C virus, respiratory syncytia virus, coronavirus, flavivirus, poliovirus, acellular pertussis, rotavirus, pneumococcus antigens (i.e. PCV15, PCV20), varicella, MMR and meningococcal antigens. In some embodiments, the active agent is a tumor associated antigen chosen from http s : / / www. zhang- 1 ab . or g / caatlas / , the contents of which are incorporated by reference in its entirety. In some embodiments, the disclosure relates to a method of inducing an antigen-specific immune response in a subject in need thereof comprising administering to the subject a therapeutically or prophylactically effective amount of one or a combination of two or more active agents that are antigens integrated within the microneedle array.
[0212] In certain embodiments, the active agent compound may include small molecule compounds. The term “small molecule” refers to natural or synthetic molecules including peptides, peptidomimetics, amino acids, amino acid analogs, nucleotides, nucleotide analogs, and organic or inorganic compounds having a molecular weight less than about 10,000 grams per mole, such as less than about 5,000 grams per mole, such as less than about 1,000 grams per mole, such as less than about 500 grams per mole.
[0213] In certain embodiments, the active agent compound may include antibiotics. The term “antibiotic” refers to compounds that act as antimicrobial, bacteriostatic, or bactericidal agents,ATTORNEY DOCKET NO. STFD-037-PCT PATENTincluding but not limited to penicillins, cephalosporins, penems, carbapenems, monobactams, aminoglycosides, sulfonamides, macrolides, tetracyclines, lincosides, quinolones, chloramphenicol, vancomycin, metronidazole, rifampin, isoniazid, spectinomycin, trimethoprim, and sulfamethoxazole.
[0214] In certain embodiments, the active agent compound may include steroids and steroid derivatives (e.g., estrogen, progesterone, testosterone, androsterone, cholesterol, norethindrone, digoxigenin, cholic acid, deoxycholic acid, chenodeoxycholic acid), boron-containing compounds (eg., carboranes), chemotherapeutic agents, enediynes (e g., calicheamicins, esperamicins, dynemicin, neocarzinostatin chromophore, kedarcidin chromophore), heavy metal complexes (e.g., cisplatin), hormone antagonists (e.g., tamoxifen), oligonucleotides, peptides, proteins, antibodies, photodynamic agents (e.g., rhodamine 123), radionuclides (e.g., 1-131, Re-186, Re-188, Y-90, Bi-212, At-211, Sr-89, Ho-166, Sm-153, Cu-67, Cu-64), toxins (e.g., ricin), and transcription-based pharmaceuticals.
[0215] In certain embodiments, the active agent compound may include analgesics and antiinflammatory agents, including acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, narcotics, anticonvulsants, and local anesthetics. Examples include ibuprofen, naproxen, aspirin, fenoprofen, flurbiprofen, ketoprofen, oxaprozin, diclofenac sodium, etodolac, indomethacin, ketorolac, sulindac, tolmetin, meclofenamate, mefenamic acid, nabumetone, piroxicam, and COX-2 inhibitors. Combination drugs such as acetaminophen with codeine, hydrocodone, or oxycodone may also be included.
[0216] In certain embodiments, the active agent compound may be formulated with one or more pharmaceutically acceptable excipients. The excipients may include stabilizers, binders, disintegrants, lubricants, preservatives, flavoring agents, diluents, and combinations thereof. Examples include sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate, calcium carbonate, methylcellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, gelatin, gum arabic, sodium bicarbonate, magnesium stearate, sodium lauryl sulfate, citric acid, menthol, sodium benzoate, phenol, benzyl alcohol, polysorbate 20 or 80, and other commonly used pharmaceutical excipients.
[0217] In certain embodiments, the active agent compound may be formulated in a pharmaceutical composition comprising a carrier or diluent. The composition may be prepared in solid, semi-solid, or liquid form, including powders, granules, solutions, suspensions, emulsions, or injectableATTORNEY DOCKET NO. STFD-037-PCT PATENTformulations. Tn some embodiments, the composition may be formulated in an aqueous buffer such as acetate, citrate, succinate, or phosphate buffer, optionally including isotonic agents (e.g., sodium chloride, sugars), surfactants, and preservatives.
[0218] In some embodiments, the composition may be lyophilized and include cryoprotectants such as sucrose, trehalose, lactose, maltose, or mannitol. In other embodiments, the composition may include stabilizers and additives configured to maintain the activity of the active agent during storage and delivery.
[0219] In certain embodiments, the components described herein, including the applicator systems, microneedle arrays, substrates, reservoirs, and structural elements, may be formed from a variety of materials selected based on mechanical, chemical, and biological properties.
[0220] In some embodiments, one or more components of the systems described herein are formed from a polymeric material. The polymeric material may be selected to provide structural integrity, flexibility, biocompatibility, or controlled degradation.
[0221] In certain embodiments, the polymeric material may include, but is not limited to, polycaprolactone, polyglycolic acid, polylactic acid, polylactic-co-glycolic acid, polyethylene glycol, thiol-enes, anhydrides, polyacrylic acid, polymethyl methacrylate, polyvinyl alcohol, polyvinylpyrrolidone, vinyl carbonates, vinyl esters, acrylamides, hyaluronic acid, chitosan, collagen, gelatin, carboxymethylcellulose, and blends or copolymers thereof.
[0222] In some embodiments, the polymeric material may include polyethylene glycol di methacryl ate (PEGDMA) or trimethylolpropane triacrylate (TMPTA) monomer.
[0223] In certain embodiments, components of the applicator systems, including the body and structural elements, may be formed from engineering polymers or thermoplastics. Such materials may include polycarbonates, polyvinyl chloride (PVC), polyurethanes, polyethers, polyamides, polyimides, or copolymers thereof.
[0224] In some embodiments, the material may include polyethylene terephthalate (PET), polybutylene terephthalate (PBT), polyethylene naphthalate, or glycol-modified polyethylene terephthalate (PETG). Additional materials may include acrylonitrile butadiene styrene (ABS), polystyrene, polypropylene, polyethylene, and combinations thereof.
[0225] In certain embodiments, the materials may include polyester-based materials, including poly(alkylene terephthalates), poly(alkylene adipates), poly(alkylene sebacates), poly(alkylene isophthalates), poly(alkylene naphthalene-dicarboxylates), and related copolymers. AdditionalATTORNEY DOCKET NO. STFD-037-PCT PATENTexamples include lactic acid polymers and copolymers such as polylactide and poly(lactide-co-glycolide), as well as polycarbonates and polyamides.
[0226] In certain embodiments, one or more components of the microneedle arrays may be formed from biodegradable or dissolvable materials.
[0227] As used herein, the term “biodegradable” refers to materials that are capable of being decomposed or degraded by biological processes, including enzymatic or microbial action. In some embodiments, biodegradable materials may degrade over a period of time following insertion into tissue.
[0228] In some embodiments, the polymeric material may be dissolvable in an aqueous medium. For example, the material may dissolve in water over a period of 0.01 hours or more, such as 0.05 hours or more, such as 0.1 hours or more, such as 0.5 hours or more, such as 1 hour or more, such as 2 hours or more, such as 6 hours or more, such as 12 hours or more, such as 18 hours or more, such as 24 hours or more, such as 36 hours or more, such as 48 hours or more, such as 72 hours or more, such as 96 hours or more, such as 120 hours or more, such as 144 hours or more, and including 168 hours or more.
[0229] In certain embodiments, the substrate or backing layer of a microneedle array patch may be formed from materials configured to provide flexibility, durability, and compatibility with the microneedles and active agent compounds.
[0230] In some embodiments, backing layers may include non-woven fabrics, woven fabrics, films, porous bodies, foamed bodies, paper materials, composite materials, or combinations thereof.
[0231] Non-woven materials may include polyolefin resins such as polyethylene and polypropylene; polyester resins such as polyethylene terephthalate, polybutylene terephthalate, and polyethylene naphthalate; rayon, polyamide, poly(ester ether), polyurethane, polyacrylic resins, polyvinyl alcohol, and copolymers thereof.
[0232] Film materials may include polyolefin resins, polyacrylic resins, polyester resins, polyvinyl alcohol, polyvinyl chloride, polystyrene, polyurethane, polyacrylonitrile, fluoropolymers, ethylene-vinyl acetate copolymers, and polysulfones.
[0233] Paper materials may include impregnated paper, coated paper, wood-free paper, Kraft paper, glassine paper, synthetic paper, and combinations thereof.ATTORNEY DOCKET NO. STFD-037-PCT PATENT
[0234] In some embodiments, the backing layer may be insoluble in water and may be configured to maintain structural integrity when exposed to moisture for extended periods.
[0235] In certain embodiments, the systems described herein may include a pressure-sensitive adhesive configured to secure a microneedle array patch to a tissue surface.
[0236] In some embodiments, the adhesive may include polybutene-based adhesives, polyisobutylene adhesives, acrylic or acrylate copolymers, carboxylated polymers, or combinations thereof.
[0237] Examples of suitable adhesive compositions include commercially available formulations such as Indopol® materials (e.g., Indopol® H-1900) and Panalane® materials. In certain embodiments, the adhesive may include acrylate-based copolymers such as Duro-Tak® formulations.
[0238] In some embodiments, the adhesive may be configured to maintain contact with the tissue surface for extended periods while allowing for removal without substantial irritation.Methods of Use
[0239] In certain embodiments, the systems described herein may be used to insert a microneedle array into tissue of a subject, deliver a substance to the subject, extract a biological fluid from the subject, or perform a combination thereof. The methods may be carried out using the applicator systems described herein to facilitate controlled and repeatable transdermal access. In some embodiments, methods may be carried out using the applicator systems described herein to facilitate controlled, single-use transdermal access. Methods of extracting interstitial fluid or blood samples from a subject are disclosed in which, in some aspects, collared embodiments of applicator system physically separate into two components upon application of a force sufficient for the needles of an array to penetrate the skin of a subject. In some embodiments, a collar portion of the application system detaches from the needle array and its platform after applying a first threshold, second threshold or threshold force onto the applicator. In such methods bodily fluid in the form of a sample in the needle and / or a reservoir in fluid communication to the needle is briefly stored in the applicator until analysis of the sample. In some embodiments, the stored bodily fluid is transferred to an analytical device or container configured for use with analytical device. In some embodiments, methods of using the disclosed system comprises transferring bodily fluid from the microneedle array to a container configured for docking and analysis, such as a cuvette, test tube, 96-well microtiter plate or other vessel suitable for assessment. In some embodiments, methods ofATTORNEY DOCKET NO. STFD-037-PCT PATENTthe disclosure further comprise performing an analytical step on the bodily fluid including for example, mass spectroscopy, wavelength absorbance assays, density assessment or exposure to chemiluminescent or fluorescent antigen-specific or protein-specific substrates for detection of biological components in the fluid.
[0240] In some embodiments, a method of inserting a microneedle array into a subject includes applying a mechanical force to an applicator system coupled to the microneedle array, where the applied force is transmitted through one or more structural elements of the applicator system to the microneedle array. The applied force may be increased until a predetermined force threshold is reached, at which point the structural elements undergo a mechanical transition, thereby facilitating insertion of the microneedle array into the tissue. The mechanical transition may include fracture, elastic deformation, plastic deformation, or combinations thereof, and may result in a reduction in resistance to further displacement of the applicator system.
[0241] In certain embodiments, insertion of the microneedle array occurs to a controlled depth based on the predetermined force threshold. By configuring the structural elements to transition at a defined threshold, the method may reduce variability in insertion depth across different users and provide a more consistent insertion profile.
[0242] In some embodiments, the method includes positioning the microneedle array at a predetermined distance from a tissue surface prior to insertion. The applicator system may be used to align and stabilize the microneedle array relative to the tissue before application of force. The microneedle array may be applied to a variety of tissues, including skin, mucosal tissue, eye tissue, liver tissue, lung tissue, heart tissue, pancreas tissue, or other biological tissues. In certain embodiments, the subject is a mammal, including a human, although the methods may also be applied to other animals such as rodents, dogs, cats, livestock, or horses.
[0243] In certain embodiments, the microneedle array is used to deliver an active agent compound to a subject. The active agent compound may be contained within the microneedles, coated onto one or more surfaces of the microneedles, or delivered through the microneedles from a reservoir in fluid communication with the microneedle array. Delivery may occur upon insertion of the microneedles into the tissue or over a period of time following insertion.
[0244] In some embodiments, the microneedle array is maintained in contact with the tissue for a period of time sufficient to deliver a therapeutically effective amount of the active agent compound. For example, delivery may occur over a period of about 30, 60, 90, or 120 seconds.ATTORNEY DOCKET NO. STFD-037-PCT PATENTDelivery may occur over about 0.1 hours, 0.3 hours, 0.5 hours or more, such as about 1 hour or more, such as 2 hours or more, such as 4 hours or more, such as 8 hours or more, such as 12 hours or more, such as 24 hours or more, such as 48 hours or more, such as 72 hours or more, such as 96 hours or more, such as 120 hours or more, such as 144 hours or more, and including 168 hours or more.
[0245] In certain embodiments, the microneedle array may be configured for extended or multiday delivery of an active agent compound. For example, delivery may occur over a period of 1 day or more, such as 2 days or more, such as 4 days or more, such as 7 days or more, such as 14 days or more, and including 30 days or more. In some embodiments, delivery may occur over a period of from 2 days to 30 days, such as from 3 days to 28 days, such as from 4 days to 21 days, such as from 5 days to 14 days, and including from 6 days to 10 days.
[0246] In certain embodiments, the microneedle array is used to collect a biological fluid from a subject. The biological fluid may include interstitial fluid, dermal fluid, blood, or other biological fluids. Upon insertion of the microneedle array into the tissue, one or more micro-scale openings may be formed, enabling fluid to enter the microneedles, for example through capillary action or pressure gradients generated during insertion.
[0247] In some embodiments, the microneedle array is maintained in contact with the tissue for a period of time sufficient to collect a desired volume of biological fluid. For example, collection may occur over a period of about 1 second or more, such as about 5 seconds or more, such as about 10 seconds or more, such as about 15 seconds or more, such as about 30 seconds or more, such as 1 minute or more, such as 5 minutes or more, such as 10 minutes or more, such as 15 minutes or more, such as 30 minutes or more, such as 1 hour or more, such as 2 hours or more, such as 3 hours or more, such as 6 hours or more, such as 12 hours or more, such as 18 hours or more, and including 24 hours or more.
[0248] In certain embodiments, the methods may include multiple application intervals in which a microneedle array is applied to the subject, removed, and replaced with a new microneedle array. In some embodiments, two or more dosage intervals may be used, such as three or more, such as four or more, such as five or more, and including ten or more dosage intervals.
[0249] In certain embodiments, the time between application intervals may vary depending on the treatment protocol or physiology of the subject. For example, the time between intervals may be 1 day or more, such as 2 days or more, such as 3 days or more, such as 4 days or more, such as 5ATTORNEY DOCKET NO. STFD-037-PCT PATENTdays or more, such as 6 days or more, such as 7 days or more, such as 10 days or more, and including 30 days or more. In some embodiments, the time between intervals may be from about 2 days to about 30 days, such as from about 3 days to about 28 days, such as from about 4 days to about 21 days, such as from about 5 days to about 14 days, and including from about 6 days to about 10 days.
[0250] In some embodiments, subsequent microneedle arrays may be applied to the same location on the subject or to different locations. In certain embodiments, subsequent applications may include the same or different active agent compounds, and the amount or concentration of the active agent may be adjusted between intervals.
[0251] In certain embodiments, the microneedle array is removed from the subject after a selected period of time. For example, the microneedle array may be maintained in contact with the subject for about 15 seconds or more, about 30 seconds or more, about 45 second or more, about 1 minute or more, about 5 minutes or more, about 0.5 hours or more, such as about 1 hour or more, such as 2 hours or more, such as 4 hours or more, such as 8 hours or more, such as 12 hours or more, such as 24 hours or more, such as 36 hours or more, such as 48 hours or more, such as 60 hours or more, such as 72 hours or more, such as 96 hours or more, such as 120 hours or more, such as 144 hours or more, and including 168 hours or more.
[0252] In certain embodiments, the microneedle array may be removed after a period of 168 hours or less, such as 144 hours or less, such as 120 hours or less, such as 96 hours or less, such as 72 hours or less, such as 48 hours or less, such as 24 hours or less, such as 12 hours or less, such as 8 hours or less, such as 4 hours or less, and including 2 hours or less.
[0253] In certain embodiments, the microneedle arrays are configured to be non-irritating to the skin of the subject at the site of application. The quality of the skin may remain substantially unchanged during and after application, with minimal or no observable redness, swelling, or irritation.
[0254] In some embodiments, skin irritation may be evaluated using standard techniques, including visual observation or scoring systems such as the Draize scale. The skin may be evaluated for erythema, edema, or other indicators of irritation at selected time intervals during and after application.
[0255] In certain embodiments, the systems described herein, including microneedle arrays, substrates, and applicator components, may be manufactured using a variety of fabricationATTORNEY DOCKET NO. STFD-037-PCT PATENTtechniques selected based on desired geometry, material properties, and functional performance. The microneedles and applicator components may be formed separately and subsequently assembled, or may be fabricated as an integrated structure. In some embodiments, the components are formed from polymeric materials using additive manufacturing techniques or molding processes.
[0256] In certain embodiments, one or more components of the systems described herein are fabricated using a high-resolution additive manufacturing process. Such methods may include irradiating a polymerizable composition positioned between a build elevator and a build surface to form a polymerized region. For example, a method may include irradiating the polymerizable composition to form a first polymerized region in contact with a build elevator while maintaining a non-polymerized region adjacent a build surface, followed by displacing the build elevator away from the build surface and repeating irradiation and displacement steps to progressively form a three-dimensional structure. These steps may be repeated a plurality of times, such as 2 or more times, such as 3 or more, such as 4 or more, such as 5 or more, such as about 10 or more, such as about 20 or more, such as about 30 or more, such as about 40 or more, such as about 50 or more, such as about 100 or more, such as about 250 or more, such as about 500 or more, and including about 1000 or more times.
[0257] In certain embodiments, the additive manufacturing process comprises continuous liquid interface production (CLIP) or a related high-resolution digital light projection process. In such processes, the polymerizable composition may be irradiated through a build surface while the build elevator is displaced relative to the build surface. The polymerizable composition may include a polymerization inhibitor, such as oxygen, which forms a “dead zone” adjacent the build surface where polymerization is inhibited. This configuration may enable continuous formation of a three-dimensional structure without adhesion to the build surface. In some embodiments, the build elevator may be displaced in increments of about 0.001 pm or more, such as 0.005 pm or more, such as 0.01 pm or more, such as 0.05 pm or more, such as 0.1 pm or more, such as 0.5 pm or more, such as about 1 pm or more, such as about 2 pm or more, such as about 3 pm or more, such as about 4 pm or more, such as about 5 pm or more, and including about 10 pm or more, with some embodiments including displacement ranges from about 0.001 pm to about 20 pm. The polymerizable composition may be supplied continuously or in discrete increments during fabrication.ATTORNEY DOCKET NO. STFD-037-PCT PATENT
[0258] In certain embodiments, the polymerizable composition is irradiated using a light source that may comprise a broadband or narrowband source. Suitable light sources may include halogen lamps, deuterium arc lamps, xenon arc lamps, light emitting diodes (LEDs), laser diodes, or other optical sources. In some embodiments, the light source emits wavelengths from 400 nm to 1000 nm or within a narrower spectral range. In certain embodiments, the light source operates in a pulsed or stroboscopic mode, providing periodic flashes of light at a frequency of 0.01 kHz or greater, such as 0.05 kHz or greater, such as 0.1 kHz or greater, such as 0.5 kHz or greater, such as 1 kHz or greater, such as 2.5 kHz or greater, such as 5 kHz or greater, such as 10 kHz or greater, such as 25 kHz or greater, such as 50 kHz or greater, and including 100 kHz or greater. The duration of each pulse may be 0.000001 ms or more, such as 0.000005 ms or more, such as 0.00001 ms or more, such as 0.00005 ms or more, such as 0.0001 ms or more, such as 0.0005 ms or more, such as 0.001 ms or more, such as 0.005 ms or more, such as 0.01 ms or more, such as 0.05 ms or more, such as 0.1 ms or more, such as 0.5 ms or more, such as 1 ms or more, such as 2 ms or more, such as 3 ms or more, such as 4 ms or more, such as 5 ms or more, such as 10 ms or more, such as 25 ms or more, such as 50 ms or more, such as 100 ms or more, and including 500 ms or more.
[0259] In certain embodiments, the fabrication process includes determining a focal plane on the build surface. This may be achieved by projecting an image onto the build surface and adjusting the position of the build surface or optical components until the image is in focus. In some embodiments, the build surface may be displaced by 1 pm or more, such as 5 pm or more, such as 10 pm or more, such as 50 pm or more, such as 100 pm or more, and including 500 pm or more, with some embodiments including displacements of 400 pm or less. In certain embodiments, an image stack comprising multiple projected image patterns may be generated and analyzed to determine the focal plane.
[0260] In certain embodiments, active agent compounds may be incorporated into microneedles during or after fabrication. In some embodiments, the active agent compound is applied to the microneedles by coating techniques such as dip-coating or spray coating, while in other embodiments the active agent is applied as a dry powder. In certain embodiments, the active agent is introduced into a lattice microstructure by contacting the microneedles with a fluid composition containing the active agent, allowing the active agent to be drawn into the lattice structure via capillary action. The microneedles may be immersed in the composition for a period of 0.01 minutes or more, such as 0.05 minutes or more, such as 0.1 minutes or more, such as 0.5 minutesATTORNEY DOCKET NO. STFD-037-PCT PATENTor more, such as 1 minute or more, such as 5 minutes or more, such as 10 minutes or more, such as 30 minutes or more, such as 60 minutes or more, and including 6 hours or more.
[0261] In certain embodiments, the applicator components, including the body and structural elements, may be fabricated using the same additive manufacturing techniques described above or using molding processes such as injection molding. The materials used for such components may include polymeric materials such as polypropylene, polyethylene, polycarbonate, acrylonitrile butadiene styrene (ABS), polystyrene, polyester resins, polyamides, polyurethanes, polyacrylic resins, and combinations thereof.
[0262] The disclosure also relates to kits are provided for use with the systems and methods described herein. The kits may include one or more components configured to facilitate insertion of a microneedle array into a subject and, in some embodiments, delivery of a substance or extraction of a biological fluid.
[0263] In some embodiments, a kit includes a microneedle array and an applicator system configured to insert the microneedle array into tissue of a subject. The applicator system may include a body and one or more structural elements configured to undergo a mechanical transition at a predetermined force threshold, as described herein. The microneedle array may be provided as a separate component configured to be coupled to the applicator system prior to use, or may be integrated with the applicator system as a single unit.
[0264] In certain embodiments, the kit includes a plurality of microneedle arrays. The microneedle arrays may be individually packaged or collectively packaged within a common container. In some embodiments, the microneedle arrays may differ from one another, for example in microneedle geometry, active agent content, or intended use.
[0265] In some embodiments, the kit may further include one or more active agent compounds. The active agent compound may be pre-loaded into the microneedle array, contained within a reservoir, or provided separately in a container for later application or loading into the system.
[0266] In certain embodiments, the kit may include one or more auxiliary components, such as a backing layer, adhesive layer, or overlay configured to secure the microneedle array to a tissue surface. The backing layer may include a pressure-sensitive adhesive configured to maintain contact with the tissue for a selected period of time.
[0267] In some embodiments, the kit may include a reservoir or fluid-handling component configured to deliver a substance to a subject or to collect a biological fluid from a subject. InATTORNEY DOCKET NO. STFD-037-PCT PATENTcertain embodiments, the reservoir may be pre-filled with a fluid or configured to receive a fluid during use.
[0268] In certain embodiments, the kit may further include instructions for use. The instructions may be provided in printed form, such as a package insert or label, or in electronic form, such as a digital file or website. The instructions may describe, for example, methods of coupling the microneedle array to the applicator system, applying the system to a subject, and removing the system after use.
[0269] In some embodiments, the kit may be configured for single-use applications, while in other embodiments the kit may be configured for multiple uses, for example by including multiple microneedle arrays configured to be used sequentially with a single applicator system.EXAMPLESExample 1. Characterization of Force as a Function of Structural Element Number
[0270] Applicator systems were fabricated with varying numbers of structural elements configured as struts. The applicator systems were designed such that the structural elements would undergo a mechanical transition, including fracture, when subjected to an applied force.
[0271] Applicator systems were fabricated from polymeric materials including UMA 90 and KeySplint Hard resins. Each structural element had a cross-sectional area of approximately 0.25 mm2. Compression testing was performed in n = 5 replicates for each applicator system configuration.
[0272] A force was applied to each applicator system, and the force required to induce the mechanical transition was measured. The number of structural elements in each applicator system was varied while maintaining other parameters substantially constant.
[0273] As shown in FIG. 16, the results demonstrated that the force required to induce the mechanical transition increased with increasing number of structural elements. Applicator systems having a greater number of struts exhibited higher resistance to deformation and required greater applied force to reach the predetermined force threshold. The activation force increased approximately linearly with increasing strut number. These results demonstrate that the force threshold of the applicator system can be tuned by adjusting the number of structural elements.Example 2. Characterization of Force as a Function of Structural Element ThicknessATTORNEY DOCKET NO. STFD-037-PCT PATENT
[0274] Applicator systems were fabricated with structural elements having different cross-sectional dimensions. The structural elements were formed from polymeric materials, including UMA 90 and KeySplint Hard resins.
[0275] Applicator systems included eight structural elements configured as breakable struts. The cross-sectional dimensions of the struts ranged from approximately 0.3 mm x 0.3 mm to approximately 0.7 mm x 0.7 mm. Compression testing was performed in n = 5 replicates for each applicator system configuration.
[0276] A force was applied to each applicator system, and the force required to induce fracture or deformation of the structural elements was measured. The thickness of the structural elements was varied while other parameters were maintained substantially constant.
[0277] As shown in FIG. 17, the results demonstrated that increasing the thickness and total cross-sectional area of the structural elements resulted in an increase in the force required to induce the mechanical transition. Structural elements with larger cross-sectional areas exhibited greater mechanical strength and required higher applied forces to fracture. These results demonstrate that the force threshold of the applicator system can be tuned by adjusting the geometry of the structural elements.Example 3. Reproducibility of Tuned Applicator Activation Force
[0278] Applicator systems were designed to exhibit a target activation force of approximately 50 N. Applicator systems were fabricated from different polymeric materials, including Carbon UMA 90 resin, KeySplint Hard resin, and injection-molded polypropylene.
[0279] Applicator systems included eight structural elements configured as breakable struts. The cross-sectional area of the struts was selected based on the ultimate tensile strength of each material.
[0280] Compression testing was performed using a mechanical testing system under uniaxial compression at a constant displacement rate. Force-displacement curves were generated for each applicator system in n = 5 replicates.
[0281] As shown in FIGS. 18A-18D, the applicator systems consistently activated at forces near the target activation force of approximately 50 N despite being fabricated from different materials. The results demonstrated reproducible activation behavior and showed that the activation threshold can be predictably tuned based on material properties and structural geometry.Example 4. Ex Vivo Skin Penetration CharacterizationATTORNEY DOCKET NO. STFD-037-PCT PATENT
[0282] Applicator systems were evaluated for skin penetration performance ex vivo using excised porcine skin. Microneedle array patches included a plurality of polymeric microneedles arranged in a square grid configuration.
[0283] Each microneedle had a base width of approximately 650 pm, a latticed body portion having a height of approximately 1200 pm, a tip angle of approximately 23 degrees, and an overall microneedle height of approximately 1600 pm. The microneedles were arranged with a pitch of approximately 1600 pm.
[0284] Microneedle arrays were applied to the excised porcine skin using three different application methods: (1) controlled thumb pressure of approximately 30 N applied for approximately 10 seconds (‘thumb”), (2) a tunable applicator having an impact distance of approximately 3 mm and configured to activate at approximately 30 N (“TAPP-1”), and (3) a tunable applicator having an impact distance of approximately 5 mm and configured to activate at approximately 30 N (“TAPP -2”).
[0285] Following application, the skin tissue was fixed and analyzed using optical coherence tomography (OCT) to determine penetration depth of the microneedles into the tissue.
[0286] As shown in FIGS. 19A-19B, application using the tunable applicator systems resulted in significantly increased penetration depth compared to force-equivalent thumb pressure alone. Thumb pressure produced an average penetration depth of approximately 576 pm, while applicator systems having impact distances of approximately 3 mm and approximately 5 mm produced average penetration depths of approximately 873 pm and approximately 917 pm, respectively.
[0287] The applicator systems also demonstrated relatively uniform penetration across the microneedle arrays. Standard deviations in penetration depth ranged from approximately 104 pm to approximately 133 pm across the tested groups.
[0288] Statistical analysis demonstrated significant improvement in penetration depth for the applicator systems relative to thumb pressure application. These results demonstrate that the tunable applicator systems facilitate more consistent and deeper insertion of microneedles into tissue surfaces compared to manual pressure application alone.
[0289] Representative OCT images of penetration profiles are shown in FIG. 19B.Example 5. Puncture Efficacy of Applicator Systems
[0290] Applicator systems assembled with microneedle array patches were evaluated for puncture efficacy in excised porcine skin using trypan blue staining.ATTORNEY DOCKET NO. STFD-037-PCT PATENT
[0291] Applicator systems fabricated from injection-molded polypropylene and from 3D-printed UMA 90 resin were assembled with polymeric microneedle arrays and applied to excised porcine skin. Following application, trypan blue dye was applied to the skin surface to identify puncture sites generated by insertion of the microneedles through the stratum corneum.
[0292] The applicator systems produced puncture sites across substantially all microneedle locations of the array, demonstrating approximately 100% puncture efficacy. These results demonstrate that the tunable applicator systems facilitate reliable and uniform engagement of microneedle arrays with tissue surfaces.
[0293] Although the disclosure has been described with reference to exemplary embodiments, it is not limited thereto. Those skilled in art will appreciate that numerous changes and modifications may be made to the preferred embodiments of the disclosure and that such changes and modifications may be made without departing from the true spirit of the disclosure. It is therefore intended that the appended claims be construed to cover all such equivalent variations as fall within the true spirit and scope of the disclosure. All referenced journal articles, patents, and other publications disclosed herein are incorporated by reference herein in their entireties.
Claims
ATTORNEY DOCKET NO. STFD-037-PCT PATENTCLAIMS1. An applicator for inserting a microneedle array into a subject, the applicator comprising:a body; andone or more structural elements operably coupled to the body and configured to transmit an applied force to the microneedle array, wherein the one or more structural elements comprise one or more breakable or compliant connections configured to undergo a mechanical transition when the applied force reaches a predetermined force threshold; andwherein the mechanical transition facilitates insertion of the microneedle array into the subject.
2. The applicator of claim 1, wherein the mechanical transition comprises fracture of at least a portion of the structural elements.
3. The applicator of claim 1, wherein the one or more structural elements comprise one or more frangible members.
4. The applicator of claim 1, wherein the one or more structural elements comprise one or more of a strut, beam, membrane, bar, truss, or combination thereof.
5. The applicator of claim 1, wherein the structural elements comprise one or more preweakened regions configured to initiate fracture at the predetermined force threshold.
6. The applicator of claim 5, wherein the pre-weakened regions comprise reduced cross-sectional regions, notches, perforations, or stress concentrators.
7. The applicator of claim 1, wherein the mechanical transition comprises a macrostructural change in the applicator.
8. The applicator of claim 1, wherein the predetermined force threshold is defined by one or more of(a) a geometry of the structural elements;(b) a material composition of the structural elements; and(c) a thickness of the structural elements.ATTORNEY DOCKET NO. STFD-037-PCT PATENT9. The applicator of claim 1 , wherein the one or more structural elements comprise a plurality of struts.
10. The applicator of claim 9, wherein a number of the plurality of struts is selected to achieve the predetermined force threshold.
11. The applicator of claim 9, wherein a cross-sectional dimension of the plurality of struts is selected to achieve the predetermined force threshold.
12. The applicator of claim 1, wherein the predetermined force threshold is within a range of about 5 N to about 250 N.
13. The applicator of claim 12, wherein the predetermined force threshold is within a range of about 10 N to about 170 N.
14. The applicator of claim 8, wherein the predetermined force threshold is selected based on a mechanical property of a material of the structural elements.
15. The applicator of claim 1, wherein the mechanical transition is irreversible.
16. The applicator of claim 1, wherein the mechanical transition comprises elastic deformation of the structural elements.
17. The applicator of claim 1, wherein the mechanical transition is partially reversible.
18. The applicator of claim 1, wherein the mechanical transition occurs only once during use of the applicator.
19. The applicator of claim 18, wherein the applicator is configured such that the mechanical transition provides a visual, tactile, or audible indication of actuation.
20. The applicator of claim 1, wherein the mechanical transition results in a reduction in resistance to further displacement of the body.
21. The applicator of claim 1, wherein the one or more structural elements comprise a first set of structural elements and a second set of structural elements configured to undergo mechanical transitions at different force thresholds.ATTORNEY DOCKET NO. STFD-037-PCT PATENT22. The applicator of claim 21, wherein the first set of structural elements is configured to transition at a lower force than the second set.
23. The applicator of claim 1, further comprising a coupling interface configured to engage a microneedle array.
24. The applicator of claim 23, wherein the coupling interface is configured for reversible coupling.
25. The applicator of claim 23, wherein the coupling interface is configured for irreversible coupling.
26. The applicator of claim 23, wherein the coupling interface comprises an alignment feature selected from a notch, groove, hole, protrusion, or cantilever hook.
27. The applicator of claim 1, wherein the applicator is configured to position the microneedle array at a predetermined distance from a tissue surface prior to insertion.
28. The applicator of claim 27, wherein the predetermined distance is selected to control insertion depth of the microneedle array.
29. The applicator of claim 1, wherein the applicator comprises a first component configured to contact a tissue surface and a second component comprising the structural elements.
30. The applicator of claim 1, wherein the structural elements are configured to transmit the applied force through a defined load path to the microneedle array.
31. The applicator of claim 1, wherein the applied force comprises a mechanical stimulus applied by a user.
32. The applicator of claim 1, wherein the applicator is configured to be disposable after a single use.
33. The applicator of claim 1, wherein the applicator is formed by injection molding.
34. A kit compri sing :a microneedle array; andATTORNEY DOCKET NO. STFD-037-PCT PATENTthe applicator of any one of claims 1-33;wherein the applicator is configured to insert the microneedle array into a subject when the predetermined force threshold is reached.
35. The kit of claim 34, wherein the microneedle array comprises a plurality of microneedles arranged on a substrate.
36. The kit of claim 34, wherein the microneedle array comprises microneedles having a lattice microstructure.
37. The kit of claim 36, wherein the lattice microstructure comprises a plurality of lattice cell units.
38. The kit of claim 36, wherein the lattice microstructure comprises a gradient in lattice density.
39. The kit of claim 36, wherein the lattice microstructure is configured to wick a fluid by capillary action.
40. The kit of claim 36, wherein the lattice microstructure is configured to contain or transport a fluid.
41. The kit of claim 34, wherein the microneedle array is configured for delivery of a therapeutic agent or extraction of a biological fluid.
42. A method of inserting a microneedle array into a subject, the method comprising:applying a force to an applicator coupled to the microneedle array;increasing the applied force until a predetermined force threshold is reached; causing one or more structural elements of the applicator to undergo a mechanical transition at the predetermined force threshold; andinserting the microneedle array into the subject.
43. The method of claim 42, wherein the mechanical transition comprises fracture of at least a portion of the structural elements.ATTORNEY DOCKET NO. STFD-037-PCT PATENT44. The method of claim 42, wherein the mechanical transition comprises elastic deformation of the structural elements.
45. The method of claim 42, wherein the applied force is increased until the structural elements fracture at the predetermined force threshold.
46. The method of claim 42, wherein the predetermined force threshold is selected to achieve a target insertion depth of the microneedle array.
47. The method of claim 42, wherein insertion of the microneedle array occurs to a controlled depth based on the predetermined force threshold.
48. The method of claim 42, wherein the method reduces variability in insertion depth across different users.
49. The method of claim 42, wherein the mechanical transition occurs only once and renders the applicator unsuitable for reuse.
50. The method of claim 42, further comprising positioning the microneedle array at a predetermined distance from a tissue surface prior to applying the force.
51. The method of claim 42, wherein the mechanical transition generates a user-perceptible indication comprising an audible, tactile, or visual signal during insertion.
52. The method of claim 42, wherein the method comprises sequentially applying force to cause a first mechanical transition and a second mechanical transition at different force thresholds.
53. The method of claim 42, further comprising delivering a substance to the subject through the microneedle array.
54. The method of claim 42, further comprising extracting a biological fluid from the subject through the microneedle array.
